Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Lung Cancer

  Free Subscription


Articles published in Clin Lung Cancer

Retrieve available abstracts of 507 articles:
HTML format



Single Articles


    July 2024
  1. SHARMA P, Mahadevia H, Donepudi S, Kujtan L, et al
    A Novel EGFR Germline Mutation in Lung Adenocarcinoma: Case Report and Literature Review.
    Clin Lung Cancer. 2024;25:479-482.
    PubMed    


  2. KUDO Y, Nakamura T, Matsubayashi J, Ichinose A, et al
    AI-driven Characterization of Solid Pulmonary Nodules on CT Imaging for Enhanced Malignancy Prediction in Small-sized Lung Adenocarcinoma.
    Clin Lung Cancer. 2024;25:431-439.
    PubMed     Abstract available


  3. PETRINI I, Bruno R, Di Stefano I, Aprile V, et al
    A patient with a Germline (p.R776H) EGFR Mutation With Multiple Lung Cancers Harboring Different Somatic EGFR Mutations.
    Clin Lung Cancer. 2024;25:e238-e242.
    PubMed    


    June 2024
  4. SHAH AT, Blanchard I, Padda SK, Wakelee HA, et al
    Molecular Characteristics and Pretreatment Neutrophil-to-Lymphocyte Ratio as Predictors of Durable Clinical Benefit from Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2024 Jun 19:S1525-7304(24)00133.
    PubMed     Abstract available


  5. ZHANG Y, Chen Z, Chen G, Huang Y, et al
    The Design for a Phase II, Randomized, Multicenter Study of CtDNA-Guided Treatment With Furmonertinib Combined Therapy or Furmonertinib Alone for Untreated Advanced EGFR Mutant Non-small-cell Lung Cancer Patients: The FOCUS-C Study.
    Clin Lung Cancer. 2024 Jun 10:S1525-7304(24)00111.
    PubMed     Abstract available


  6. MUSCOLINO P, Scimone C, Sapuppo E, Micali V, et al
    Gefitinib Resensitization After a TKI-Free Interval in Osimertinib Resistant Non-Small-Cell Lung Cancer: A Glimpse of Hope in Time of Crisis?
    Clin Lung Cancer. 2024 Jun 10:S1525-7304(24)00112.
    PubMed    


  7. WU X, Stabile LP, Burns TF
    The Emerging Role of Immune Checkpoint Blockade for the Treatment of Lung Cancer Brain Metastases.
    Clin Lung Cancer. 2024 Jun 10:S1525-7304(24)00124.
    PubMed     Abstract available


  8. ROBINSON LA, Tanvetyanon T, Robinson NA, Bryant S, et al
    Surgery and Stereotactic Radiotherapy for Stage I Small-Cell Lung Carcinoma: A 25-Year Experience.
    Clin Lung Cancer. 2024 Jun 8:S1525-7304(24)00110.
    PubMed     Abstract available


  9. GALLINA FT, Chiappetta M, Taje R, Forcella D, et al
    Neutrophil-to-Lymphocyte Ratio and Risk of Nodal Metastasis in Early-Stage Lung Adenocarcinoma: A Brief Report From a Multicentric Analysis.
    Clin Lung Cancer. 2024;25:e196-e200.
    PubMed    


  10. PARK JE, Hong KS, Choi SH, Lee SY, et al
    Durvalumab Consolidation After Chemoradiotherapy in Elderly Patients With Unresectable Stage III NSCLC: A Real-World Multicenter Study.
    Clin Lung Cancer. 2024;25:354-364.
    PubMed     Abstract available


  11. WU E, Reznicek J, Yeldandi AV, Patel JD, et al
    Neoadjuvant Therapy Before Resection of Primary Pulmonary Lymphoepithelial Carcinoma.
    Clin Lung Cancer. 2024;25:376-379.
    PubMed    


  12. FENG A, Huang Y, Zeng Y, Shao Y, et al
    Improvement of Prediction Performance for Radiation Pneumonitis by Using 3-Dimensional Dosiomic Features.
    Clin Lung Cancer. 2024;25:e173-e180.
    PubMed     Abstract available


    May 2024
  13. AWIDI M, Mier-Hicks A, Perimbeti S, Attwood K, et al
    Patients' Preferences for Adjuvant Osimertinib in Non-Small-Cell Lung Cancer After Complete Surgical Resection: What Makes It Worth It to Patients?
    Clin Lung Cancer. 2024 May 29:S1525-7304(24)00082.
    PubMed     Abstract available


  14. CHRISTENSEN NL, Gouliaev A, McPhail S, Lyratzopoulos G, et al
    Routes to Diagnosis in Danish Lung Cancer Patients: Emergency Presentation, Age and Smoking History-A Population-Based Cohort Study.
    Clin Lung Cancer. 2024 May 25:S1525-7304(24)00108.
    PubMed     Abstract available


  15. KLEEMISS M, Muller CE, Schneider M, Strotmann R, et al
    Tepotinib in a Patient With Advanced Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Undergoing Concomitant Hemodialysis for Renal Failure: A Case Report.
    Clin Lung Cancer. 2024 May 25:S1525-7304(24)00109.
    PubMed    


  16. THOSANI DS, Meredith LT, West R, Till BM, et al
    Association Between Utilization of Services and Perioperative Outcomes for Lung Cancer Resection.
    Clin Lung Cancer. 2024 May 20:S1525-7304(24)00097.
    PubMed     Abstract available


  17. ROUSSEAU G, Dantoing E, Leturgie B, Tillon-Strozyk J, et al
    Brief Report: Carboplatin, Weekly Paclitaxel and Pembrolizumab in Elderly Patients for Advanced Non-Small Cell Lung Cancer With PD-L1 < 50%: Real-World Data.
    Clin Lung Cancer. 2024 May 18:S1525-7304(24)00084.
    PubMed    


  18. IWAI C, Jo T, Konishi T, Fujita A, et al
    Interstitial Pneumonitis Following Sequential Administration of Programmed Death-1/Programmed Death-Ligand1 Inhibitors and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors For Non-Small Cell Lung Cancer: A Matched-Pair Cohort Study Using a
    Clin Lung Cancer. 2024 May 11:S1525-7304(24)00067.
    PubMed     Abstract available


  19. MINNE RL, Luo NY, Traynor AM, Huang M, et al
    Genomic and Immune Landscape Comparison of MET Exon 14 Skipping and MET-Amplified Non-small Cell Lung Cancer.
    Clin Lung Cancer. 2024 May 10:S1525-7304(24)00080.
    PubMed     Abstract available


  20. TAYLOR M, Evison M, Michael S, Obale E, et al
    Pre-Operative Measures of Systemic Inflammation Predict Survival After Surgery for Primary Lung Cancer.
    Clin Lung Cancer. 2024 May 8:S1525-7304(24)00077.
    PubMed     Abstract available


  21. ZHANG W, Tian S, Li X, Chen Y, et al
    ETV6-NTRK2 Fusion in a Patient With Metastatic Pulmonary Atypical Carcinoid Successfully Treated With Entrectinib: A Case Report and Review of the Literature.
    Clin Lung Cancer. 2024;25:215-224.
    PubMed     Abstract available


  22. TILL BM, Grenda T, Tidwell T, Wickes B, et al
    Brief Report: Nonmalignant Surgical Resection Among Individuals with Screening-Detected Versus Incidental Lung Nodules.
    Clin Lung Cancer. 2024;25:e129-e132.
    PubMed    


    April 2024
  23. SRIDHAR A, West HJ, Singhi EK
    Brief Report on Global Clinician Practices in the First-Line Management of Metastatic Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2024 Apr 30:S1525-7304(24)00068.
    PubMed     Abstract available


  24. TANVETYANON T, Chen DT, Gray JE
    Timeliness of EGFR/ALK Inhibitor Treatment and Survival in Lung Cancer: A Population-Based Analysis.
    Clin Lung Cancer. 2024 Apr 30:S1525-7304(24)00078.
    PubMed     Abstract available


  25. LU S, Zhou Q, Liu X, Du Y, et al
    Updated Efficacy and Safety of Lorlatinib in a Phase 2 Study in Chinese Patients With Previously Treated Advanced ALK-Positive Non-small Cell Lung Cancer.
    Clin Lung Cancer. 2024 Apr 30:S1525-7304(24)00079.
    PubMed     Abstract available


  26. WONG LY, Choudhary S, Kapula N, Lin M, et al
    Barriers to Completing Low Dose Computed Tomography Scan for Lung Cancer Screening.
    Clin Lung Cancer. 2024 Apr 27:S1525-7304(24)00070.
    PubMed     Abstract available


  27. NONAKA Y, Isaka M, Matsushima K, Katsumata S, et al
    Prediction of Pleural Lavage Cytology According to Thin-Section Computed Tomography in Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2024 Apr 16:S1525-7304(24)00053.
    PubMed     Abstract available


  28. FANTONI A, Warburton L, Solomon B, Alexander M, et al
    Completion of Pembrolizumab in Advanced Non-Small Cell Lung Cancer-Real World Outcomes After Two Years of Therapy (COPILOT).
    Clin Lung Cancer. 2024 Apr 15:S1525-7304(24)00051.
    PubMed     Abstract available


  29. JIANG Z, Li Q, Ruan J, Li Y, et al
    Machine Learning-Based Prediction of Pathological Responses and Prognosis After Neoadjuvant Chemotherapy for Non-Small-Cell Lung Cancer: A Retrospective Study.
    Clin Lung Cancer. 2024 Apr 12:S1525-7304(24)00049.
    PubMed     Abstract available


  30. ORDING AG, Christensen TD, Skjoth F, Noble S, et al
    Risk of Venous Thromboembolism in Patients With Stage III and IV Non-Small-Cell Lung Cancer: Nationwide Descriptive Cohort Study.
    Clin Lung Cancer. 2024 Apr 11:S1525-7304(24)00047.
    PubMed     Abstract available


  31. NILSSEN Y, Brustugun OT, Fjellbirkeland L, Gronberg BH, et al
    Small Cell Lung Cancer in Norway: Patterns of Care by Health Region and Survival Trends.
    Clin Lung Cancer. 2024 Apr 10:S1525-7304(24)00046.
    PubMed     Abstract available


  32. MILLS MN, Uno A, Li P, Liveringhouse C, et al
    Clinical Outcomes of Patients with Non-Small Cell Lung Cancer Leptomeningeal Disease Following Receipt of EGFR-Targeted Therapy, Immune-Checkpoint Blockade, Intrathecal Chemotherapy, or Radiation Therapy Alone.
    Clin Lung Cancer. 2024 Apr 10:S1525-7304(24)00048.
    PubMed     Abstract available


  33. ROBERTS HN, Solomon B, Harden S, Lingaratnam S, et al
    Utility of 30-Day Mortality Following Systemic Anti-Cancer Treatment as a Quality Indicator in Advanced Lung Cancer.
    Clin Lung Cancer. 2024 Apr 6:S1525-7304(24)00045.
    PubMed     Abstract available


  34. PAN H, Chen H, Kong W, Ning J, et al
    Video-Assisted Thoracoscopic Surgery Versus Thoracotomy Following Neoadjuvant Immunochemotherapy in Resectable Stage III Non-Small Cell Lung Cancer Among Chinese Populations: A Multi-Center Retrospective Cohort Study.
    Clin Lung Cancer. 2024 Apr 2:S1525-7304(24)00042.
    PubMed     Abstract available


    March 2024
  35. DONINGTON J, Hu X, Zhang S, Song Y, et al
    Real-World Neoadjuvant Treatment Patterns and Outcomes in Resected Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2024 Mar 22:S1525-7304(24)00041.
    PubMed     Abstract available


  36. DJUNADI TA, Oh Y, Lee J, Yu J, et al
    Redefining Clinical Hyperprogression: The Incidence, Clinical Implications, and Risk Factors of Hyperprogression in Non-Small Cell Lung Cancer Treated with Immunotherapy.
    Clin Lung Cancer. 2024 Mar 16:S1525-7304(24)00036.
    PubMed     Abstract available


  37. GARON EB, Cho BC, Luft A, Alatorre-Alexander J, et al
    A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study.
    Clin Lung Cancer. 2024 Mar 15:S1525-7304(24)00038.
    PubMed    


  38. MARMARELIS ME, Scholes DG, McGrath CM, Priore SF, et al
    Brief Report: Impact of Reflex Testing on Tissue-Based Molecular Genotyping in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2024 Mar 12:S1525-7304(24)00037.
    PubMed    


  39. NOURMOHAMMADI N, Liang THP, Sadigh G
    Patient-Provider Lung Cancer Screening Discussions: An Analysis of a National Survey.
    Clin Lung Cancer. 2024 Mar 2:S1525-7304(24)00034.
    PubMed     Abstract available


  40. MOGHANAKI D, Taylor J, Bryant AK, Vitzthum LK, et al
    Lung Cancer Survival Trends in the Veterans Health Administration.
    Clin Lung Cancer. 2024 Mar 2:S1525-7304(24)00035.
    PubMed     Abstract available


  41. ARDESHIR-LARIJANI F, Maniar R, Goyal S, Loehrer PJ, et al
    Trop-2 Expression and Its Impact on Survival in Thymic Epithelial Tumors: Brief Report.
    Clin Lung Cancer. 2024;25:180-185.
    PubMed    


  42. JENNINGS EM, Camidge DR, Gadgeel S, Barker S, et al
    Trial Design and Optimal Determination of CNS Activity of Small Molecule Targeted Therapy in NSCLC.
    Clin Lung Cancer. 2024;25:91-99.
    PubMed     Abstract available


  43. VERMA S, Young S, Kennedy TAC, Carvalhana I, et al
    Detection of Circulating Tumor DNA After Stereotactic Ablative Radiotherapy in Patients With Unbiopsied Lung Tumors (SABR-DETECT).
    Clin Lung Cancer. 2024;25:e87-e91.
    PubMed     Abstract available


  44. GONZALEZ-MOSQUERA LF, Rous FA, Rogers A, Smith N, et al
    ALK Rearrangement Positive Lung Adenocarcinoma in Pregnancy Treated With Alectinib: A Case Report.
    Clin Lung Cancer. 2024;25:e77-e80.
    PubMed     Abstract available


  45. BORGHETTI P, Facheris G, Ciammella P, Galaverni M, et al
    Sterotactic Ablative Radiotherapy in a Multicentric Series of Oligometastatic SCLC: The SAMOS Cohort.
    Clin Lung Cancer. 2024;25:151-158.
    PubMed     Abstract available


  46. INNO A, Picece V, Bogina G, Settanni G, et al
    Niraparib for the Treatment of Metastatic NSCLC in a Patient With BRCA2 Germinal Mutation: A Case Report.
    Clin Lung Cancer. 2024;25:175-179.
    PubMed    


    February 2024
  47. GEORGE B, Baydoun A, Bhat S, Bailey L, et al
    Invasive Nodal Staging via Endobronchial Ultrasound and Outcome in Patients Treated with Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer - Results from a Single Institution Study.
    Clin Lung Cancer. 2024 Feb 24:S1525-7304(24)00030.
    PubMed     Abstract available


  48. KHOKHAR B, Chiang B, Iglay K, Reynolds K, et al
    QT-Interval Prolongation, Torsades de Pointes, and Heart Failure With EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Systematic Review.
    Clin Lung Cancer. 2024 Feb 17:S1525-7304(24)00016.
    PubMed     Abstract available


  49. PONVILAWAN B, Mahadevia H, Qasim H, Sharma P, et al
    Brief Report: Evaluating the Impact of Perioperative Immune Checkpoint Inhibitor in the Treatment of Patients with Resectable Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Clin Lung Cancer. 2024 Feb 15:S1525-7304(24)00014.
    PubMed    


  50. D'AIELLO A, Stiles B, Ohri N, Levy B, et al
    Perioperative Immunotherapy for Non-Small Cell Lung Cancer: Practical Application of Emerging Data and New Challenges.
    Clin Lung Cancer. 2024 Feb 13:S1525-7304(24)00015.
    PubMed     Abstract available


  51. WU Y, Zhao Y, Wu Y, Chen H, et al
    A Retrospective Real-World Study of Prognostic Factors Associated With EGFR Mutated Lung Cancer With Leptomeningeal Metastasis.
    Clin Lung Cancer. 2024 Feb 8:S1525-7304(24)00012.
    PubMed     Abstract available


  52. OKUMA Y, Shintani Y, Sekine I, Shukuya T, et al
    Efficacy of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Metastatic Non-Small Cell Lung Cancer Patients with Poor Performance Status and Epidermal Growth Factor Receptor Mutations: Findings from the Japanese Lung Cancer Registry Data
    Clin Lung Cancer. 2024 Feb 2:S1525-7304(24)00007.
    PubMed     Abstract available


    January 2024
  53. FIROZ WA, Sen F, Kiuru M, Huang V, et al
    A Case of ROS1-Fusion Non-Small Cell Lung Cancer with Acquired BRAF Mutation Developing Unusual Skin Metastasis.
    Clin Lung Cancer. 2024 Jan 30:S1525-7304(24)00011.
    PubMed    


  54. MATSUBARA T, Yamaguchi M, Shimokawa M, Okamoto I, et al
    Phase II Trial of Adjuvant Atezolizumab Therapy in Elderly Patients with Completely Resected Stage II/III Non-Small Cell Lung Cancer: RELIANCE Trial.
    Clin Lung Cancer. 2024 Jan 28:S1525-7304(24)00010.
    PubMed     Abstract available


  55. KAMIGAICHI A, Hamada A, Tsuboi M, Yoshimura K, et al
    A Multi-Institutional, Randomized, Phase III Trial Comparing Anatomical Segmentectomy and Lobectomy for Clinical Stage IA3 Pure-Solid Non-Small-Cell Lung Cancer: West Japan Oncology Group Study WJOG16923L (STEP UP Trial).
    Clin Lung Cancer. 2024 Jan 26:S1525-7304(24)00006.
    PubMed     Abstract available


  56. TSUBOKAWA N, Mimae T, Mimura T, Kamigaichi A, et al
    Clinical Significance of Preserving Pulmonary Function After Lung Resection in Early-Stage Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2024 Jan 26:S1525-7304(24)00005.
    PubMed     Abstract available


  57. WALIANY S, Neal JW, Engel-Nitz N, Lam C, et al
    HER2-Mutant Advanced and/or Metastatic Non-Small-Cell Lung Cancer: A US Electronic Health Records Database Analysis of Clinical Characteristics, Treatment Practice Patterns, and Outcomes.
    Clin Lung Cancer. 2024 Jan 18:S1525-7304(24)00004.
    PubMed     Abstract available


  58. RODRIGUEZ-ABREU D, Bosch-Barrera J, Gray JE, Ahn MJ, et al
    STAR-121: A Phase III Randomized Study of Domvanalimab and Zimberelimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Untreated Metastatic Non-Small Cell Lung Cancer With No Actionable Gene Alterations.
    Clin Lung Cancer. 2024 Jan 6:S1525-7304(23)00267.
    PubMed     Abstract available


  59. CHEN Q, Wang J, Wang X, Yin Y, et al
    Influence of Tumor Cavitation on Assessing the Clinical Benefit of Anti-PD1 or PD-L1 Inhibitors in Advanced Lung Squamous Cell Carcinoma.
    Clin Lung Cancer. 2024;25:29-38.
    PubMed     Abstract available


  60. MAO S, Rosner S, Forde PM, Chaft JE, et al
    A Brief Report on the Patterns of Mediastinal Nodal Failure in Resectable Stage IB-IIIA NSCLC Treated With Neoadjuvant Immunotherapy Combinations, a Secondary Analysis of a Prospective Trial.
    Clin Lung Cancer. 2024;25:e67-e71.
    PubMed    


  61. HAYASAKA K, Takeda H, Sakurada A, Matsumura Y, et al
    Clinical, Genomic, and Transcriptomic Featurses of Lung Adenocarcinoma With Uncommon EGFR Mutation.
    Clin Lung Cancer. 2024;25:e43-e51.
    PubMed     Abstract available


  62. ORLANDI R, Leuzzi G, Rolli L, Ferrari M, et al
    Long-Term Survival Analysis of Pleural Mesothelioma Patients Undergoing Surgery: Brief Report From a Tertiary Referral Centre.
    Clin Lung Cancer. 2024;25:e5-e10.
    PubMed     Abstract available


  63. GAO M, Wang L, Jing F, Zhang F, et al
    The Efficacy of Pemigatinib in Advanced NSCLC With FGFR Aberration: Case Report.
    Clin Lung Cancer. 2024;25:e62-e66.
    PubMed    


  64. KASHIZAKI F, Chen H, Miyasaka A, Tsuchiya N, et al
    Safety of Readministration of EGFR-TKI After Onset of Interstitial Lung Disease in Advanced EGFR-Mutated NSCLC: A Systematic Review and Meta-Analysis.
    Clin Lung Cancer. 2024;25:e52-e57.
    PubMed     Abstract available


  65. JURICA JM, Carsten B, Balakhani S, Haag MM, et al
    CSF Cytology Identifies Mechanisms of Tyrosine Kinase Inhibitor Resistance in Patient With EGFR-Mutated NSCLC With CNS Progression.
    Clin Lung Cancer. 2024;25:77-79.
    PubMed    


  66. SOO RA, de Marinis F, Han JY, Ho JC, et al
    TARGET: A Phase II, Open-Label, Single-Arm Study of 5-Year Adjuvant Osimertinib in Completely Resected EGFR-Mutated Stage II to IIIB NSCLC Post Complete Surgical Resection.
    Clin Lung Cancer. 2024;25:80-84.
    PubMed     Abstract available


  67. LU K, Woodward BD, Boys J, Onaitis M, et al
    Brief Report: Evaluation of Molecular Profiling Strategies for Neoadjuvant Osimertinib in Stage IIIA EGFR-Mutant NSCLC.
    Clin Lung Cancer. 2024;25:e58-e61.
    PubMed    


  68. FRIEDES C, Yegya-Raman N, Zhang S, Iocolano M, et al
    Patterns of Failure in Metastatic NSCLC Treated With First Line Pembrolizumab and Use of Local Therapy in Patients With Oligoprogression.
    Clin Lung Cancer. 2024;25:50-60.
    PubMed     Abstract available


    December 2023
  69. DETTERBECK F, Ely S, Udelsman B, Blasberg J, et al
    So Now We Know-Reflections on the Extent of Resection for Stage I Lung Cancer.
    Clin Lung Cancer. 2023 Dec 28:S1525-7304(23)00262.
    PubMed     Abstract available


  70. JANG C, Lau SC, Velcheti V
    To Crush or Not to Crush: Administering Dabrafenib and Trametinib Through a Nasogastric Tube in a Critically Ill Patient With Nonsmall Cell Lung Cancer - A Case Report and Review of Literature of Targeted Therapies Given Through Enteral Feeding Tubes.
    Clin Lung Cancer. 2023 Dec 27:S1525-7304(23)00270.
    PubMed     Abstract available


  71. RAMANATHAN S, Hochstedler KA, Laucis AM, Movsas B, et al
    Predictors of Early Hospice or Death in Patients With Inoperable Lung Cancer Treated With Curative Intent.
    Clin Lung Cancer. 2023 Dec 27:S1525-7304(23)00283.
    PubMed     Abstract available


  72. BARSOUK A, Friedes C, Iocolano M, Doucette A, et al
    Plunging Into the PACIFIC: Outcomes of Patients With Unresectable KRAS-Mutated Non-Small Cell Lung Cancer Following Definitive Chemoradiation and Durvalumab Consolidation.
    Clin Lung Cancer. 2023 Dec 22:S1525-7304(23)00266.
    PubMed     Abstract available


  73. PRELAJ A, Ganzinelli M, Provenzano L, Mazzeo L, et al
    APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research.
    Clin Lung Cancer. 2023 Dec 22:S1525-7304(23)00269.
    PubMed     Abstract available


  74. VERSCHUEREN MV, Peters BJ, Bloem LT, Kruik VR, et al
    Pembrolizumab Plus Chemotherapy Per PD-L1 Stratum In Patients With Metastatic Non-Small Cell Lung Cancer: Real-World Effectiveness Versus Trial Efficacy.
    Clin Lung Cancer. 2023 Dec 20:S1525-7304(23)00268.
    PubMed     Abstract available


  75. PILON Y, Rokah M, Seitlinger J, Sepesi B, et al
    Transitioning to Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: Trends and Surgical Outcomes in a Regionalized Pulmonary Oncology Network.
    Clin Lung Cancer. 2023 Dec 19:S1525-7304(23)00264.
    PubMed     Abstract available


  76. CAO J, Zhang C, Zhang X, Liu L, et al
    The Clinical Outcomes of Thoracoscopic Versus Open Lobectomy for Non-Small-Cell Lung Cancer After Neoadjuvant Therapy: A Multi-Center Retrospective Cohort Study.
    Clin Lung Cancer. 2023 Dec 16:S1525-7304(23)00263.
    PubMed     Abstract available


  77. SCHOENMAEKERS J, Dijkstra J, van der Wekken A, Paats M, et al
    In-depth Analysis of Lorlatinib-related neurocognitive Adverse Events in Patients With Non-small-cell Lung Cancer.
    Clin Lung Cancer. 2023 Dec 13:S1525-7304(23)00261.
    PubMed     Abstract available


  78. MATHIOT L, Nigen B, Goronflot T, Hiret S, et al
    Prognostic Impact of TP53 Mutations in Metastatic Nonsquamous Non-small-cell Lung Cancer.
    Clin Lung Cancer. 2023 Dec 13:S1525-7304(23)00260.
    PubMed     Abstract available


  79. CALI DAYLAN AE, Maia CM, Attarian S, Guo X, et al
    HIV Associated Lung Cancer: Unique Clinicopathologic Features and Immune Biomarkers Impacting Lung Cancer Screening and Management.
    Clin Lung Cancer. 2023 Dec 12:S1525-7304(23)00259.
    PubMed     Abstract available


  80. FAN Y, Drilon A, Chiu CH, Loong HHF, et al
    Brief Report: Updated Efficacy and Safety Data From an Integrated Analysis of Entrectinib in Locally Advanced/Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2023 Dec 7:S1525-7304(23)00258.
    PubMed    


  81. OU SI, Prawitz T, Lin HM, Hong JL, et al
    Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment Comparison.
    Clin Lung Cancer. 2023 Dec 4:S1525-7304(23)00254.
    PubMed     Abstract available


  82. GROSS AJ, Sheikh S, Kharouta M, Chaung K, et al
    The Impact of Prophylactic Cranial Irradiation and Consolidative Thoracic Radiation Therapy for Extensive Stage Small-Cell Lung Cancer in the Transition to the Chemo-Immunotherapy Era: A Single Institution Series.
    Clin Lung Cancer. 2023;24:696-705.
    PubMed     Abstract available


  83. VISONA G, Spiller LM, Hahn S, Hattingen E, et al
    Machine-Learning-Aided Prediction of Brain Metastases Development in Non-Small-Cell Lung Cancers.
    Clin Lung Cancer. 2023;24:e311-e322.
    PubMed     Abstract available


  84. FARIA N, Lacerda C, Lopes J, Viana C, et al
    PET-CT SUV(max) and Endobronchial Ultrasound Features for Prediction of Malignancy: A Prospective Study.
    Clin Lung Cancer. 2023;24:753-760.
    PubMed     Abstract available


  85. LI S, Chen M, Wang Y, Li X, et al
    An Effective Malignancy Prediction Model for Incidentally Detected Pulmonary Subsolid Nodules Based on Current and Prior CT Scans.
    Clin Lung Cancer. 2023;24:e301-e310.
    PubMed     Abstract available


  86. VINDUM HH, Kristensen K, Christensen NL, Madsen HH, et al
    Outcome of Incidental Pulmonary Nodules in a Real-World Setting.
    Clin Lung Cancer. 2023;24:673-681.
    PubMed     Abstract available


  87. GHANEM P, Murray JC, Hsu M, Guo MZ, et al
    Clinical and Genomic Characterization of Long-Term Responders Receiving Immune Checkpoint Blockade for Metastatic Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2023 Dec 1:S1525-7304(23)00255.
    PubMed     Abstract available


    November 2023
  88. PORTE M, Vaudron A, Crequit P, Vaugier L, et al
    A Multicenter Study Assessing the Real-World Use and Effectiveness of First-Line Chemotherapy Plus Immunotherapy in Advanced Small-Cell Lung Cancer (SCLC) Patients.
    Clin Lung Cancer. 2023 Nov 23:S1525-7304(23)00252.
    PubMed     Abstract available


  89. LIU J, Xiang Y, Fang T, Zeng L, et al
    Advances in the Diagnosis and Treatment of Advanced Non-Small-Cell Lung Cancer With EGFR Exon 20 Insertion Mutation.
    Clin Lung Cancer. 2023 Nov 23:S1525-7304(23)00253.
    PubMed     Abstract available


  90. RIUDAVETS M, Auclin E, Mosteiro M, Dempsey N, et al
    Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2023 Nov 22:S1525-7304(23)00242.
    PubMed     Abstract available


  91. HUI C, Marquez C, Lau B, Das M, et al
    Patient Selection and Outcomes for Hypofractionated Accelerated Radiation and Concurrent Chemotherapy for Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2023 Nov 21:S1525-7304(23)00243.
    PubMed     Abstract available


  92. OHRI N, Chudgar NP, Vimolratana M, Cheng H, et al
    Comments on "Effect of Surgical Treatment for N2-Positive c-Stage III Non-Small Cell Lung Carcinoma in the "PACIFIC" Era".
    Clin Lung Cancer. 2023 Nov 14:S1525-7304(23)00227.
    PubMed    


  93. HUI C, Brown E, Wong S, Das M, et al
    Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer: Protocol for a Bayesian Optimal Phase I/II Trial.
    Clin Lung Cancer. 2023 Nov 8:S1525-7304(23)00230.
    PubMed     Abstract available


  94. SAWA K, Ihara Y, Imai T, Sugimoto A, et al
    Lack of Association Between Immunotherapy and Improvement of Survival for Non-small Cell Lung Cancer Patients With Hemodialysis: A Nationwide Retrospective Cohort Study.
    Clin Lung Cancer. 2023 Nov 7:S1525-7304(23)00229.
    PubMed     Abstract available


  95. ADACHI H, Ito H, Isaka T, Saito H, et al
    Sufficient Multidisciplinary Discussion Can Make Patients' Outcomes Better in the Treatment for Stage III Non-Small-Cell Lung Carcinoma - Reply to Ohri et al.
    Clin Lung Cancer. 2023 Nov 3:S1525-7304(23)00228.
    PubMed    


  96. WOLF J, Souquet PJ, Goto K, Cortot A, et al
    Improved Survival Outcomes in Patients With MET-Dysregulated Advanced NSCLC Treated With MET Inhibitors: Results of a Multinational Retrospective Chart Review.
    Clin Lung Cancer. 2023;24:641-650.
    PubMed     Abstract available


  97. FRICKE J, Wang J, Gallego N, Mambetsariev I, et al
    Selpercatinib and Pralsetinib Induced Chylous Ascites in RET-Rearranged Lung Adenocarcinoma: A Case Series.
    Clin Lung Cancer. 2023;24:666-671.
    PubMed    


  98. MALLAEV M, Chirindel AF, Lardinois D, Tamm M, et al
    3D-Quantitated Single Photon Emission Computed Tomography/Computed Tomography: Impact on intended Management Compared to Lung Perfusion Scan in Marginal Candidates for Pulmonary Resection.
    Clin Lung Cancer. 2023;24:621-630.
    PubMed     Abstract available


  99. LEE KH, Chung JH, Cho S, Lee JS, et al
    Differential Prognostic Value of Vascular Invasion in Resected Lung Adenocarcinomas According to Epidermal Growth Factor Receptor Mutational Status.
    Clin Lung Cancer. 2023;24:e291-e299.
    PubMed     Abstract available


  100. ASAO T, Shukuya T, Mimori T, Goto Y, et al
    Study Design and Rationale for Marble Study: A Phase II Trial of Atezolizumab (MPDL3280A) Plus Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Thymic Carcinoma (JTD2101).
    Clin Lung Cancer. 2023;24:e247-e253.
    PubMed     Abstract available


    October 2023
  101. PIRZADEH M, Lagina M, Wood C, Valley T, et al
    Barriers to Timely Lung Cancer Care in Early Stage Non-Small Cell Lung Cancer and Impact on Patient Outcomes.
    Clin Lung Cancer. 2023 Oct 31:S1525-7304(23)00226.
    PubMed     Abstract available


  102. QIN A, Wells L, Malhotra B, Gadgeel S, et al
    A Phase II Trial of Pevonedistat and Docetaxel in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2023 Oct 26:S1525-7304(23)00224.
    PubMed     Abstract available


  103. FLOREZ N, Kiel L, Riano I, Patel S, et al
    Lung Cancer in Women: The Past, Present, and Future.
    Clin Lung Cancer. 2023 Oct 20:S1525-7304(23)00212.
    PubMed     Abstract available


  104. ADACHI H, Morohoshi T, Shintani Y, Okami J, et al
    Benefit of Adjuvant Chemotherapy for Patients Older Than 75 Years With Completely Resected p-Stage II-IIIA Non-Small-Cell Lung Cancer: A Retrospective Cohort Study Using Japanese Nationwide Real-World Data.
    Clin Lung Cancer. 2023 Oct 12:S1525-7304(23)00192.
    PubMed     Abstract available


  105. ENJO-BARREIRO JR, Ruano-Ravina A, Perez-Rios M, Kelsey K, et al
    Genome Wide Association Studies in Small-Cell Lung Cancer. A Systematic Review.
    Clin Lung Cancer. 2023 Oct 12:S1525-7304(23)00195.
    PubMed     Abstract available


  106. YU LEE-MATEUS A, Sawal N, Hartley C, Edell E, et al
    Efficacy of Robotic Bronchoscopy for Molecular Marker Analysis in Primary Lung Cancer.
    Clin Lung Cancer. 2023 Oct 12:S1525-7304(23)00194.
    PubMed     Abstract available


  107. LEE G, Hill LP, Schroeder MC, Kraus SJ, et al
    Adherence to Annual Lung Cancer Screening in a Centralized Academic Program.
    Clin Lung Cancer. 2023 Oct 12:S1525-7304(23)00193.
    PubMed     Abstract available


  108. ZHANG JT, Dong S, Gu WQ, Zhao N, et al
    Adjuvant Therapy-Free Strategy for Stage IB to IIIA Non-Small-Cell Lung Cancer Patients After Radical Resection Based on Longitudinal Undetectable Molecular Residual Disease: Prospective, Multicenter, Single-Arm Study (CTONG 2201).
    Clin Lung Cancer. 2023 Oct 6:S1525-7304(23)00189.
    PubMed     Abstract available


  109. KOBAT H, Elkonaissi I, Foreman E, Davidson M, et al
    Smoking, Diabetes Mellitus, and Previous Cardiovascular Disease as Predictors of Anticancer Treatment-Induced Cardiotoxicity in Non-Small-Cell Lung Cancer: A Real-World Study.
    Clin Lung Cancer. 2023 Oct 4:S1525-7304(23)00187.
    PubMed     Abstract available


  110. NAKAMICHI S, Kubota K, Matsuyama K, Misumi T, et al
    A Phase ? Study of Ubenimex Combined With Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non-Small-Cell Lung Cancer: TORG2241 (UBE-Q).
    Clin Lung Cancer. 2023 Oct 4:S1525-7304(23)00186.
    PubMed     Abstract available


    September 2023
  111. DESAI A, Smith CJ, Ashara Y, Orme JJ, et al
    Real-World Outcomes With Lurbinectedin in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung Cancer.
    Clin Lung Cancer. 2023 Sep 17:S1525-7304(23)00183.
    PubMed     Abstract available


  112. TAKADA K, Takamori S, Brunetti L, Crucitti P, et al
    Impact of Neoadjuvant Immune Checkpoint Inhibitors on Surgery and Perioperative Complications in Patients With Non-small-cell Lung Cancer: A Systematic Review.
    Clin Lung Cancer. 2023 Sep 3:S1525-7304(23)00182.
    PubMed     Abstract available


  113. TOMPKINS WP, Hwang WT, Yang YX, Singh A, et al
    Brief Report: Second-line treatment outcomes in patients with advanced NSCLC previously treated with first-line immunotherapy regimens.
    Clin Lung Cancer. 2023;24:558-562.
    PubMed     Abstract available


  114. MAZIERES J, Vioix H, Pfeiffer BM, Campden RI, et al
    MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes.
    Clin Lung Cancer. 2023;24:483-497.
    PubMed     Abstract available


  115. ASHOK KUMAR P, Karimi M, Basnet A, Seymour L, et al
    Association of Molecular Profiles and Mutational Status With Distinct Histological Lung Adenocarcinoma Subtypes. An Analysis of the LACE-Bio Data.
    Clin Lung Cancer. 2023;24:528-540.
    PubMed     Abstract available


  116. KOIKE H, Ashizawa K, Tsutsui S, Kurohama H, et al
    Differentiation Between Heterogeneous GGN and Part-Solid Nodule Using 2 D Grayscale Histogram Analysis of Thin-Section CT Image.
    Clin Lung Cancer. 2023;24:541-550.
    PubMed     Abstract available


  117. WOZNIAK AJ, Schneider B, Kalemkerian GP, Daly B, et al
    Short Report of a Phase II Trial of Nintedanib in Recurrent Malignant Pleural Mesothelioma (MPM).
    Clin Lung Cancer. 2023;24:563-567.
    PubMed    


  118. DELASOS L, Wei W, Hassan KA, Pennell NA, et al
    Clinical Outcomes With Pembrolizumab-Based Therapies in Recurrent/Refractory NSCLC After Chemoradiation and Consolidative Durvalumab.
    Clin Lung Cancer. 2023;24:e205-e213.
    PubMed     Abstract available


  119. FROST N, Bleckmann A, Griesinger F, Grohe C, et al
    Rationale and Design of the Phase II ANTELOPE Study of Atezolizumab, Carboplatin and nab-Paclitaxel vs. Pembrolizumab, Platinum and Pemetrexed in TTF-1 Negative, Metastatic Lung Adenocarcinoma (AIO-TRK-0122).
    Clin Lung Cancer. 2023;24:568-572.
    PubMed     Abstract available


    August 2023
  120. BOCHTLER T, Christopoulos P, Schlamp K, Winkler F, et al
    Management of a Pregnant ALK-Positive Lung Cancer Patient With Alectinib-Induced Pneumonitis and Bilateral Globus Pallidus Necrosis Postpartum.
    Clin Lung Cancer. 2023 Aug 30:S1525-7304(23)00181.
    PubMed    


  121. BRAMBILLA M, Beninato T, Piemontese A, Mazzeo L, et al
    Exploring the Role of Immunotherapy-Based Treatments for Advanced Non-Small-Cell Lung Cancer With Novel Driver Alterations.
    Clin Lung Cancer. 2023 Aug 23:S1525-7304(23)00149.
    PubMed     Abstract available


  122. EBADI M, Ladbury C, Liu J, Rock A, et al
    Stereotactic Body Radiation Therapy for Oligoprogressive and Oligorecurrent Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2023 Aug 22:S1525-7304(23)00180.
    PubMed     Abstract available


  123. PETRANOVIC M, McDermott S, Mercaldo S, Little BP, et al
    Impact of Baseline Interstitial Lung Abnormalities on Pneumonitis Risk in Patients Receiving Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2023 Aug 21:S1525-7304(23)00179.
    PubMed     Abstract available


  124. HONG YR, Wheeler M, Wang R, Karanth S, et al
    Patient-Provider Discussion About Lung Cancer Screening by Race and Ethnicity: Implications for Equitable Uptake of Lung Cancer Screening.
    Clin Lung Cancer. 2023 Aug 18:S1525-7304(23)00175.
    PubMed     Abstract available


  125. HASHIMOTO K, Murakami Y, Omura K, Takahashi H, et al
    Prediction of Tumor PD-L1 Expression in Resectable Non-Small Cell Lung Cancer by Machine Learning Models Based on Clinical and Radiological Features: Performance Comparison With Preoperative Biopsy.
    Clin Lung Cancer. 2023 Aug 11:S1525-7304(23)00155.
    PubMed     Abstract available


  126. MI S, Liang N, Zhang Y, Zhang Y, et al
    Effect of Sequence of Radiotherapy Combined With Immunotherapy on the Incidence of Pneumonitis in Patients With Lung Cancer: A Systematic Review and Network Meta-Analysis.
    Clin Lung Cancer. 2023 Aug 6:S1525-7304(23)00153.
    PubMed     Abstract available


  127. HUANG BT, Lin PX, Wang Y, Luo LM, et al
    Developing a Prediction Model for Radiation Pneumonitis in Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy Combined With Clinical, Dosimetric Factors, and Laboratory Biomarkers.
    Clin Lung Cancer. 2023 Aug 6:S1525-7304(23)00152.
    PubMed     Abstract available


  128. NEMALA A, Ullah A, Yacur M, Karim NA, et al
    Do Current Lung Cancer Clinical Trials Represent All Patient Populations Including Minorities?
    Clin Lung Cancer. 2023 Aug 5:S1525-7304(23)00147.
    PubMed     Abstract available


  129. OZAWA H, Matsuura Y, Hashimoto K, Ichinose J, et al
    Prognostication Using the Japanese Risk Calculator for Lung Cancer Surgery.
    Clin Lung Cancer. 2023 Aug 4:S1525-7304(23)00143.
    PubMed     Abstract available


    July 2023
  130. ADACHI H, Ito H, Isaka T, Murakami K, et al
    Effect of Surgical Treatment for N2-Positive c-stage III Non-Small Cell Lung Carcinoma in the "PACIFIC" Era.
    Clin Lung Cancer. 2023 Jul 25:S1525-7304(23)00144.
    PubMed     Abstract available


  131. RUSSO A, Scilla KA, Mehra R, Gittens A, et al
    Tracking Clonal Evolution of EGFR-Mutated Non-Small Cell Lung Cancer Through Liquid Biopsy: Management of C797S Acquired Mutation.
    Clin Lung Cancer. 2023 Jul 19:S1525-7304(23)00142.
    PubMed    


  132. MACK SJ, Collins ML, Whitehorn GL, Till BM, et al
    Intraoperative Versus Preoperative Diagnosis of Lung Cancer: Differences in Treatments and Patient Outcomes.
    Clin Lung Cancer. 2023 Jul 8:S1525-7304(23)00141.
    PubMed     Abstract available


  133. SHI Z, Wei J, Sun W, Zeng X, et al
    Efficacy of Tyrosine Kinase Inhibitors in Primary Driver-Gene-Positive Combined Small-Cell Lung Cancer: A Retrospective Study.
    Clin Lung Cancer. 2023 Jul 5:S1525-7304(23)00140.
    PubMed     Abstract available


  134. MESHULAMI N, Tavolacci S, de Miguel-Perez D, Rolfo C, et al
    Predictive Capability of PD-L1 Protein Expression for Patients With Advanced NSCLC: Any Differences Based on Histology?
    Clin Lung Cancer. 2023;24:401-406.
    PubMed     Abstract available


  135. YANG CJ, Veeramachaneni N, Hurd J, Potter AL, et al
    A National Survey of Surgeons Evaluating the Accuracy of Mediastinal Lymph Node Identification.
    Clin Lung Cancer. 2023;24:445-452.
    PubMed     Abstract available


  136. KHAIRUNNISA NI, Yamasaki F, Miyata Y, Okada M, et al
    The Efficacy of PCSK9 Inhibitors in Treating Hypercholesterolemia Caused by Lorlatinib: A Report of Two Cases.
    Clin Lung Cancer. 2023;24:e176-e178.
    PubMed    


  137. PHILLIPS WJ, Lo B, Corredor ALG, Gomes MM, et al
    A rare case of false negative ROS1 fusion in metastatic pulmonary adenocarcinoma: Case report and lessons learned.
    Clin Lung Cancer. 2023;24:e172-e175.
    PubMed    


  138. KLEEBAYOON A, Wiwanitkit V
    Correspondence on SARS-CoV-2 Vaccine Uptake Among Patients With Thoracic Malignancies.
    Clin Lung Cancer. 2023;24:e161.
    PubMed    


  139. YEGYA-RAMAN N, Friedes C, Sun L, Iocolano M, et al
    Utilization and Factors Precluding Receipt of Checkpoint Inhibitor Consolidation for Stage III NSCLC in a Large US Academic Health System.
    Clin Lung Cancer. 2023;24:474-482.
    PubMed     Abstract available


  140. NISHIO M, Paz-Ares L, Reck M, Nakagawa K, et al
    RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome.
    Clin Lung Cancer. 2023;24:415-428.
    PubMed     Abstract available


  141. LOCOCO F, Cancellieri A, Chiappetta M, Leonetti A, et al
    Salvage Surgery After First-Line Alectinib for Locally-Advanced/Metastatic ALK-Rearranged NSCLC: Pathological Response and Perioperative Results.
    Clin Lung Cancer. 2023;24:467-473.
    PubMed     Abstract available


  142. WO Y, Li H, Chen Z, Peng Y, et al
    Lobe-Specific Lymph Node Dissection May be Feasible for Clinical N0 Solid-Predominant Part-Solid Lung Adenocarcinoma With Solid Component Diameter
    Clin Lung Cancer. 2023;24:437-444.
    PubMed     Abstract available


  143. NEW ML, Hirsch EA, Feser WJ, Malkoski SP, et al
    Differences in VA and Non-VA Pulmonary Nodules: All Evaluations Are not Created Equal.
    Clin Lung Cancer. 2023;24:407-414.
    PubMed     Abstract available


    June 2023
  144. EICHHORN F, Weigert A, Nandigama R, Klotz LV, et al
    Prognostic Impact of the Immune-Cell Infiltrate in N1-Positive Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2023 Jun 28:S1525-7304(23)00139.
    PubMed     Abstract available


  145. BLASI M, Kuon J, Shah R, Bozorgmehr F, et al
    Pembrolizumab Alone or With Chemotherapy for 70+ Year-Old Lung Cancer Patients: A Retrospective Study.
    Clin Lung Cancer. 2023 Jun 22:S1525-7304(23)00136.
    PubMed     Abstract available


  146. GUO MZ, Balaji A, Murray JC, Reuss JE, et al
    Infectious Complications in Patients With Non-small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
    Clin Lung Cancer. 2023 Jun 20:S1525-7304(23)00137.
    PubMed     Abstract available


  147. SHAO H, Faris NR, Ward KD, Chen W, et al
    Lung Cancer Patients' and Caregivers' Satisfaction With Multidisciplinary Versus Serial Care in a Community Healthcare Setting: A Prospective Comparative-Effectiveness Cohort Study.
    Clin Lung Cancer. 2023 Jun 20:S1525-7304(23)00125.
    PubMed     Abstract available


  148. KOBAYASHI H, Wakuda K, Naito T, Mamesaya N, et al
    Continuous vs. Fixed 2-year Duration Immune Checkpoint Inhibitor Treatment of Patients With Non-Small Cell Lung Cancer: A Single Institution Database Analysis.
    Clin Lung Cancer. 2023 Jun 15:S1525-7304(23)00128.
    PubMed     Abstract available


  149. ZHAO S, Chen K, Shi X, Sun J, et al
    Design and Rationale for a Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Sugemalimab as Consolidation Therapy in Patients With Limited-Stage Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent or Sequential Chemor
    Clin Lung Cancer. 2023 Jun 15:S1525-7304(23)00135.
    PubMed     Abstract available


  150. CHIAPPETTA M, Sassorossi C, Lococo F, Sperduti I, et al
    Non-Small Cell Lung Cancer With N1 Involvement or Skip Metastases Presents the Same Survival Outcome: Results From a Multicentric Study.
    Clin Lung Cancer. 2023 Jun 15:S1525-7304(23)00127.
    PubMed     Abstract available


  151. SIGEL K, Silverberg MJ, Crothers K, Park L, et al
    Comparison of Stage I Non-Small-Cell Lung Cancer Treatments for Patients Living With HIV: A Simulation Study.
    Clin Lung Cancer. 2023 Jun 14:S1525-7304(23)00122.
    PubMed     Abstract available


  152. YONESAKA K, Hayashi H, Nakamura A, Sato Y, et al
    Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary Mutation in EGFR-Mutant Lung Cancer: A Single-Arm Phase II Trial.
    Clin Lung Cancer. 2023 Jun 3:S1525-7304(23)00110.
    PubMed     Abstract available


  153. SMITH JT, Puri S, Akerley W
    Brief Report: EGFR L833V/H835L Duplex-Mutated NSCLC With Leptomeningeal Carcinomatosis Responsive to Osimertinib.
    Clin Lung Cancer. 2023;24:360-361.
    PubMed    


  154. TSUTANI Y, Goldman JW, Dacic S, Yatabe Y, et al
    Adjuvant Osimertinib vs. Placebo in Completely Resected Stage IA2-IA3 EGFR-Mutated NSCLC: ADAURA2.
    Clin Lung Cancer. 2023;24:376-380.
    PubMed     Abstract available


  155. GARCIA-PARDO M, Aparicio I, Martinez I, Arregui M, et al
    Brief Report: Clinical Outcomes Using Plasma-Based Molecular Profiling to Guide Treatment Decisions in Patients With Advanced NSCLC and Limited Access to Broad Tissue Testing.
    Clin Lung Cancer. 2023;24:366-370.
    PubMed    


  156. MEADOR CB, Naranbhai V, Hambelton G, Rivera J, et al
    Brief Report: Declining Rates of SARS-CoV-2 Vaccine Uptake Among Patients With Thoracic Malignancies.
    Clin Lung Cancer. 2023;24:353-359.
    PubMed     Abstract available


  157. VIHINEN H, Jokinen A, Laajala TD, Wahid N, et al
    Antibiotic Treatment is an Independent Poor Risk Factor in NSCLC But Not in Melanoma Patients Who had Received Anti-PD-1/L1 Monotherapy.
    Clin Lung Cancer. 2023;24:295-304.
    PubMed     Abstract available


    May 2023
  158. MAJEED U, Seegobin K, Lewis J, Li S, et al
    Lung Cancer in Patients With Lynch Syndrome: Association or Coincidence?
    Clin Lung Cancer. 2023 May 31:S1525-7304(23)00109.
    PubMed     Abstract available


  159. AUNG WY, Lee CS, Morales J, Rahman H, et al
    Safety and Efficacy of Immune Checkpoint Inhibitors in Cancer Patients and Preexisting Autoimmune Disease: A Systematic Review and Meta-Analysis in Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2023 May 26:S1525-7304(23)00108.
    PubMed     Abstract available


  160. AGARWAL M, Liu A, Langlais BT, Leventakos K, et al
    Chemoimmunotherapy as the First-Line Treatment for Patients With Extensive-Stage Small-Cell Lung Cancer and an ECOG Performance Status 2 or 3.
    Clin Lung Cancer. 2023 May 26:S1525-7304(23)00107.
    PubMed     Abstract available


  161. ISAKSSON J, Berglund A, Louie K, Willen L, et al
    KRAS G12C Mutant Non-Small Cell Lung Cancer Linked to Female Sex and High Risk of CNS Metastasis: Population-based Demographics and Survival Data From the National Swedish Lung Cancer Registry.
    Clin Lung Cancer. 2023 May 11:S1525-7304(23)00096.
    PubMed     Abstract available


  162. BODOR JN, Patel JD, Wakelee HA, Levy BP, et al
    Phase II Randomized Trial of Carboplatin, Pemetrexed, and Bevacizumab With and Without Atezolizumab in Stage IV Nonsquamous Non-Small-Cell Lung Cancer Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked.
    Clin Lung Cancer. 2023 May 11:S1525-7304(23)00097.
    PubMed     Abstract available


  163. YANG MZ, Tan ZH, Li JB, Long H, et al
    Impact of the Number of Harvested Lymph Nodes on Long-Term Survival in Node-Negative Non-Small-Cell Lung Cancer: Based on Clinical Stage But Not Pathological Stage.
    Clin Lung Cancer. 2023 May 2:S1525-7304(23)00085.
    PubMed     Abstract available


  164. JOHNSON ML, Strauss J, Patel MR, Garon EB, et al
    Mocetinostat in Combination With Durvalumab for Patients With Advanced NSCLC: Results From a Phase I/II Study.
    Clin Lung Cancer. 2023;24:218-227.
    PubMed     Abstract available


  165. TRAN MC, Strohbehn GW, Karrison TG, Rouhani SJ, et al
    Brief Report: Discordance Between Liquid and Tissue Biopsy-Based Next-Generation Sequencing in Lung Adenocarcinoma at Disease Progression.
    Clin Lung Cancer. 2023;24:e117-e121.
    PubMed    


  166. KRAMER AS, Adeberg S, Kronsteiner D, Konig L, et al
    Upfront and Repeated Stereotactic Radiosurgery in Patients With Brain Metastases From NSCLC.
    Clin Lung Cancer. 2023;24:269-277.
    PubMed     Abstract available


  167. FILIPPI AR, Agustoni F, Arcangeli S, Cortinovis D, et al
    Rationale and Design of a Single-Arm, Phase 2, Multi-Center Study of Chemo-Immunotherapy Followed by Hypo-Fractionated RT and Maintenance Immunotherapy in Patients With Unresectable Stage III NSCLC: The DEDALUS Trial.
    Clin Lung Cancer. 2023;24:e122-e125.
    PubMed     Abstract available


  168. LADBURY C, Abuali T, Liu J, Watkins W, et al
    Prognostic Role of Biologically Active Volume of Disease in Patients With Metastatic Lung Adenocarcinoma.
    Clin Lung Cancer. 2023;24:244-251.
    PubMed     Abstract available


  169. GHIMIRE B, Pokharel A, Karki U, Thapa S, et al
    Anaplastic Lymphoma Kinase (ALK) Positive Neuroendocrine Tumor of Lung With Favorable Response to Alectinib (ALK Inhibitor).
    Clin Lung Cancer. 2023;24:e113-e116.
    PubMed    


  170. LING L, Zheng H, Lin H, Ge C, et al
    Adequate Number of Lymph Nodes Sampled May Determine Appropriate Surgical Modality for Early-Stage NSCLC: A Population-Based Real-World Study.
    Clin Lung Cancer. 2023;24:e141-e151.
    PubMed     Abstract available


  171. SUAITI L, Sullivan TB, Rieger-Christ KM, Servais EL, et al
    Vascular Invasion Predicts Recurrence in Stage IA2-IB Lung Adenocarcinoma but not Squamous Cell Carcinoma.
    Clin Lung Cancer. 2023;24:e126-e133.
    PubMed     Abstract available


    April 2023
  172. BILANI N, Itani M, Soweid L, Iska S, et al
    Geographic Origin may Affect Outcomes for Hispanic Patients with Non-Small Cell Lung Cancer in the United States.
    Clin Lung Cancer. 2023 Apr 29:S1525-7304(23)00084.
    PubMed     Abstract available


  173. NIKOLA N, Aleksa G, Ana R, Srdjan P, et al
    Brief Report: Predictive value of PD-L1 Expression in non-Small-Cell Lung Cancer - Should we Set the Bar Higher for Monotherapy?
    Clin Lung Cancer. 2023 Apr 27:S1525-7304(23)00083.
    PubMed    


  174. WANG KY, Lee CS, Vempati P, Sharma R, et al
    Characteristics of Patients With Second Primary Lung Cancer Following Breast Cancer: A Retrospective Descriptive Study.
    Clin Lung Cancer. 2023 Apr 26:S1525-7304(23)00074.
    PubMed     Abstract available


  175. AZZOLI C, Huynh L, Yi D, Duh MS, et al
    Authors' Response to "Letter to the Editor" Submitted by S. Wang and W. Liu (re: "Retrospective Study to Examine Prognostic Value of C-Reactive Protein in Patients With Surgically Resectable Non-Small-Cell Lung Cancer".
    Clin Lung Cancer. 2023 Apr 25:S1525-7304(23)00077.
    PubMed    


  176. WANG S, Liu W
    Comments on "Retrospective Study to Examine Prognostic Value of C-Reactive Protein in Patients With Surgically Resectable Non-Small Cell Lung Cancer".
    Clin Lung Cancer. 2023 Apr 23:S1525-7304(23)00073.
    PubMed    


  177. AZAR I, Austin A, Saha BK, Kim S, et al
    The Role of Surgery in Stage I Small Cell Lung Cancer: A National VA Database Analysis.
    Clin Lung Cancer. 2023 Apr 15:S1525-7304(23)00062.
    PubMed     Abstract available


  178. TANKEL J, Mouhanna J, Katz A, Fiset PO, et al
    The 8th Edition TNM Stage Reclassification of T4 Non-Small Cell Lung Cancer: A Granular Examination of Short and Long-Term Outcomes.
    Clin Lung Cancer. 2023 Apr 12:S1525-7304(23)00061.
    PubMed     Abstract available


  179. LI X, Zhou H, Mou K, Zheng Y, et al
    Risk Factors for Operation Complications of High Dose Rate 3-Dimensional Interstitial Brachytherapy for Lung Cancer.
    Clin Lung Cancer. 2023 Apr 8:S1525-7304(23)00059.
    PubMed     Abstract available


  180. NEZAMI N, Khorshidi F, Mansur A, Habibollahi P, et al
    Primary and Metastatic Lung Cancer: Rationale, Indications, and Outcomes of Thermal Ablation.
    Clin Lung Cancer. 2023 Apr 3:S1525-7304(23)00055.
    PubMed     Abstract available


    March 2023
  181. WELFORD J, Rafferty R, Short D, Dewhurst F, et al
    Personalised Assessment and Rapid Intervention in Frail Patients With Lung Cancer: The Impact of an Outpatient Occupational Therapy Service.
    Clin Lung Cancer. 2023 Mar 24:S1525-7304(23)00051.
    PubMed     Abstract available


  182. WEI CX, Mamdani H, Gentzler R, Kalra M, et al
    A Brief Report of a Phase II trial Evaluating Efficacy and Safety of Hypomethylating Agent Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer.
    Clin Lung Cancer. 2023 Mar 21:S1525-7304(23)00042.
    PubMed    


  183. HONG YJ, Han S, Lim JU, Kang HS, et al
    Association Between Quality of Life Questionnaire at Diagnosis and Survival in Patients With Lung Cancer.
    Clin Lung Cancer. 2023 Mar 21:S1525-7304(23)00048.
    PubMed     Abstract available


  184. OSAZUWA-PETERS OL, Wilson LE, Check DK, Roberts MC, et al
    Factors Associated With Receipt of Molecular Testing and its Impact on Time to Initial Systemic Therapy in Metastatic Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2023 Mar 20:S1525-7304(23)00049.
    PubMed     Abstract available


  185. PRADERE P, Caramella C, Salem FB, Florea V, et al
    A Patient-Centered Model of Fast-Track Lung Cancer Diagnosis.
    Clin Lung Cancer. 2023 Mar 20:S1525-7304(23)00047.
    PubMed     Abstract available


  186. SIRECI AN, Krein PM, Hess LM, Khan T, et al
    Real-World Biomarker Testing Patterns in Patients With Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) in a US Community-Based Oncology Practice Setting.
    Clin Lung Cancer. 2023 Mar 20:S1525-7304(23)00050.
    PubMed     Abstract available


  187. DURAN AO, Inanc M, Bozkurt O, Ozaslan E, et al
    Tumor Volume Is a Better Prognostic Factor than Greatest Tumor Diameter in Operated Stage I-III Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2023 Mar 4:S1525-7304(23)00040.
    PubMed     Abstract available


  188. KOUROUNI I, Suguness A, Finley J, Josan ES, et al
    Reducing Racial Disparities in the Timeliness of Potential Lung Cancer Evaluation With a Novel Application-Supported Rapid Outpatient Diagnostic Program: An Interrupted Time Series Analysis.
    Clin Lung Cancer. 2023 Mar 4:S1525-7304(23)00041.
    PubMed     Abstract available


  189. LI H, Zheng S, Lin Y, Yu T, et al
    Safety, Pharmacokinetic and Clinical Activity of Intrathecal Chemotherapy With Pemetrexed via the Ommaya Reservoir for Leptomeningeal Metastases From Lung Adenocarcinoma: A Prospective Phase I Study.
    Clin Lung Cancer. 2023;24:e94-e104.
    PubMed     Abstract available


  190. SALTMAN DL, Varga MG, Nielsen TJ, Croteau NS, et al
    27-gene Immuno-Oncology (IO) Score is Associated With Efficacy of Checkpoint Immunotherapy in Advanced NSCLC: A Retrospective BC Cancer Study.
    Clin Lung Cancer. 2023;24:137-144.
    PubMed     Abstract available


  191. HEYMACH J, Opdam F, Barve M, Gibson N, et al
    A Phase I, Open-Label, Dose Confirmation, Escalation, and Expansion Trial of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations.
    Clin Lung Cancer. 2023;24:e65-e68.
    PubMed     Abstract available


  192. BEDDOK A, Chabi-Charvillat ML, Kennel T, de Wolf J, et al
    Prospective Radiologic-Pathologic Correlation of Macroscopic Volume and Microscopic Extension of Nonsolid Lung Nodules on Thin-section CT Images for Sublobar Resection and Stereotactic Radiotherapy Planning.
    Clin Lung Cancer. 2023;24:98-106.
    PubMed     Abstract available


  193. NAKAO M, Terauchi T, Oikado K, Sato Y, et al
    Distinct Prognostic Impact of PET Findings Based on Radiological Appearance in Clinical Stage IA Lung Adenocarcinoma.
    Clin Lung Cancer. 2023;24:107-113.
    PubMed     Abstract available


  194. CHO BC, Simi A, Sabari J, Vijayaraghavan S, et al
    Amivantamab, an Epidermal Growth Factor Receptor (EGFR) and Mesenchymal-epithelial Transition Factor (MET) Bispecific Antibody, Designed to Enable Multiple Mechanisms of Action and Broad Clinical Applications.
    Clin Lung Cancer. 2023;24:89-97.
    PubMed     Abstract available


  195. BURNS L, Jani C, Radwan A, Omari OA, et al
    Implementation Challenges and Disparities in Molecular Testing for Patients With Stage IV NSCLC: Perspectives from an Urban Safety-Net Hospital.
    Clin Lung Cancer. 2023;24:e69-e77.
    PubMed     Abstract available


  196. SHAH M, Mamtani R, Marmarelis ME, Hennessy S, et al
    Chemoimmunotherapy vs. Immunotherapy for First Line Treatment of Advanced Non-small Cell Lung Cancer With a PD-L1 Expression >/=50% or >/=90.
    Clin Lung Cancer. 2023 Mar 1:S1525-7304(23)00038.
    PubMed     Abstract available


    February 2023
  197. PRELAJ A, Ganzinelli M, Trovo' F, Roisman LC, et al
    The EU-funded I(3)LUNG Project: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy.
    Clin Lung Cancer. 2023 Feb 28:S1525-7304(23)00039.
    PubMed     Abstract available


  198. IZANO MA, Sweetnam C, Zhang C, Weese JL, et al
    Brief Report on Use of Pembrolizumab With or Without Chemotherapy for Advanced Lung Cancer: A Real-World Analysis.
    Clin Lung Cancer. 2023 Feb 8:S1525-7304(23)00013.
    PubMed    


  199. AZZOLI C, Huynh L, Yi D, Duh MS, et al
    Retrospective Study to Examine Prognostic Value of C-Reactive Protein in Patients With Surgically Resectable Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2023 Feb 8:S1525-7304(23)00016.
    PubMed     Abstract available


  200. IAMS WT, Balbach ML, Phillips S, Sacher A, et al
    A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2023 Feb 8:S1525-7304(23)00018.
    PubMed     Abstract available


  201. BERNABE-CARO R, Chen Y, Dowlati A, Eason P, et al
    Current and Emerging Treatment Options for Patients With Relapsed Small-cell Lung Carcinoma: A Systematic Literature Review.
    Clin Lung Cancer. 2023 Feb 8:S1525-7304(23)00017.
    PubMed     Abstract available


  202. KAZEMI M, Ladbury C, Liu J, Glaser S, et al
    Thoracic Radiation in Limited Stage Small Cell Lung Cancer: Trends in Radiation Fractionation.
    Clin Lung Cancer. 2023 Feb 7:S1525-7304(23)00015.
    PubMed     Abstract available


  203. MIYANAGA A, Asahina H, Watanabe S, Shukuya T, et al
    A Phase I/II Study of Necitumumab Plus Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non-Small Cell Lung Cancer Study: (NEJ048A/NEXUS).
    Clin Lung Cancer. 2023 Feb 1:S1525-7304(23)00010.
    PubMed     Abstract available


    January 2023
  204. ZHU W, Love K, Gray SW, Raz DJ, et al
    Liquid Biopsy Screening for Early Detection of Lung Cancer: Current State and Future Directions.
    Clin Lung Cancer. 2023 Jan 27:S1525-7304(23)00008.
    PubMed     Abstract available


  205. RIFKIN AS, Less EM, Wei J, Shi Z, et al
    Association of Reported Candidate Monogenic Genes With Lung Cancer Risk.
    Clin Lung Cancer. 2023 Jan 26:S1525-7304(23)00009.
    PubMed     Abstract available


  206. SEBASTIAN NT, Stokes WA, Behera M, Jiang R, et al
    The Association of Improved Overall Survival with NSAIDs in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
    Clin Lung Cancer. 2023 Jan 21:S1525-7304(23)00001.
    PubMed     Abstract available


  207. NAVANI V, Meyers DE, Ruan Y, Boyne DJ, et al
    Lung Immune Therapy Evaluation (LITE) Risk, a Novel Prognostic Model for Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Blockade.
    Clin Lung Cancer. 2023 Jan 20:S1525-7304(23)00004.
    PubMed     Abstract available


  208. SPITALERI G, Trillo Aliaga P, Catania C, Signore ED, et al
    Safety of mRNA-COVID-19 Vaccines in Patients With Thoracic Cancers.
    Clin Lung Cancer. 2023;24:e19-e26.
    PubMed     Abstract available


  209. NIEF CA, No HJ, Louie CY, Vitzthum L, et al
    Regression of Malignant Pleural Mesothelioma in Absence of Chemotherapy or Surgery: A Case Series.
    Clin Lung Cancer. 2023;24:76-81.
    PubMed    


  210. GANESH A, Korpics M, Pasquinelli M, Feldman L, et al
    Increased Utilization of Stereotactic Body Radiotherapy is Associated with Decreased Disparities and Improved Survival for Early-Stage NSCLC.
    Clin Lung Cancer. 2023;24:60-71.
    PubMed     Abstract available


  211. SUI Q, Yang H, Yin J, Li M, et al
    The comparison of Lobe-Specific or Systematic Mediastinal Lymph Node Dissection for Early-Stage Lung Adenocarcinoma With Consolidation Tumor Ratio Over 0.5.
    Clin Lung Cancer. 2023;24:51-59.
    PubMed     Abstract available


  212. FU J, Tong Y, Xu Z, Li Y, et al
    Impact of TP53 Mutations on EGFR-Tyrosine Kinase Inhibitor Efficacy and Potential Treatment Strategy.
    Clin Lung Cancer. 2023;24:29-39.
    PubMed     Abstract available


    December 2022
  213. KOIZUMI T, Nishino Y, Takiguchi T, Kanda S, et al
    Epidemiological and Therapeutic Analyses in Lung Cancer Patients Over 80 Years Old in the Hokushin Region: A Retrospective Hospital Administrative Database Study.
    Clin Lung Cancer. 2022 Dec 31:S1525-7304(22)00284.
    PubMed     Abstract available


  214. TANI Y, Kaneda H, Koh Y, Tamiya A, et al
    The Impact of Estrogen Receptor Expression on Mutational Status in the Evolution of Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2022 Dec 31:S1525-7304(22)00293.
    PubMed     Abstract available


  215. CHEN M, Xu Y, Zhao J, Liu X, et al
    Comparison of Chemotherapy Plus Pembrolizumab vs. Chemotherapy Alone in EGFR-Mutant Non-small-Cell Lung Cancer Patients.
    Clin Lung Cancer. 2022 Dec 28:S1525-7304(22)00291.
    PubMed     Abstract available


  216. ASOKAN S, Pavesi F, Bains A, Qureshi MM, et al
    Frailty Index is Associated with Treatment Decisions for Stage I Non-Small Cell Lung Cancer at a High-Burden Safety-Net Hospital.
    Clin Lung Cancer. 2022 Dec 28:S1525-7304(22)00289.
    PubMed     Abstract available


  217. SANDFELD-PAULSEN B, Aggerholm-Pedersen N, Winther-Larsen A
    Pretreatment Platelet Count is a Prognostic Marker in Lung Cancer: A Danish Registry-based Cohort Study.
    Clin Lung Cancer. 2022 Dec 27:S1525-7304(22)00295.
    PubMed     Abstract available


  218. KNEUERTZ PJ, Abdel-Rasoul M, D'Souza DM, Moffatt-Bruce SD, et al
    Prevalence and Predictability of Occult Satellite Nodules in Clinical Stage Ia Non-small Cell Lung Cancer following Lobectomy.
    Clin Lung Cancer. 2022 Dec 27:S1525-7304(22)00297.
    PubMed     Abstract available


  219. KIM KN, Heintz J, Yegya-Raman N, Cohen R, et al
    Toxicities and Deaths From Intercurrent Disease Following Contemporary Postoperative Radiotherapy in Resected Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2022 Dec 25:S1525-7304(22)00296.
    PubMed     Abstract available


  220. SIDDIQI N, Pan G, Liu A, Lin Y, et al
    Timeliness of Lung Cancer Care From the Point of Suspicious Image at an Urban Safety Net Hospital.
    Clin Lung Cancer. 2022 Dec 25:S1525-7304(22)00299.
    PubMed     Abstract available


  221. WEST H, Hu X, Zhang S, Song Y, et al
    Treatment Patterns and Outcomes in Resected Early-stage Non-small Cell Lung Cancer: An Analysis of the SEER-Medicare Data.
    Clin Lung Cancer. 2022 Dec 25:S1525-7304(22)00290.
    PubMed     Abstract available


  222. ZHANG C, Kim RY, McGrath CM, Andronov M, et al
    The Performance of an Extended Next Generation Sequencing Panel Using Endobronchial Ultrasound-Guided Fine Needle Aspiration Samples in Non-Squamous Non-Small Cell Lung Cancer: A Pragmatic Study.
    Clin Lung Cancer. 2022 Dec 5:S1525-7304(22)00270.
    PubMed     Abstract available


  223. NESTERYUK V, Hamdani O, Gong R, Almog N, et al
    A Common Cell of Origin for Inflammatory Myofibroblastic Tumor and Lung Adenocarcinoma with ALK rearrangement.
    Clin Lung Cancer. 2022;23:e550-e555.
    PubMed     Abstract available


  224. BANKS KC, Ossowski S, Hung YY, Hsu DS, et al
    Comparison of Survival by Multimodal Treatment Regimen Among Malignant Pleural Mesothelioma Patients in an Integrated Health System.
    Clin Lung Cancer. 2022;23:694-701.
    PubMed     Abstract available


  225. AHN MJ, Mendoza MJL, Pavlakis N, Kato T, et al
    Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations.
    Clin Lung Cancer. 2022;23:670-685.
    PubMed     Abstract available


  226. KALAND DA, Dores GM, Nayernama A, Camilli S, et al
    U.S. Food and Drug Administration Analysis of Newly Identified Adverse Events With Lurbinectedin: Extravasation, Rhabdomyolysis, and Tumor Lysis Syndrome.
    Clin Lung Cancer. 2022;23:e556-e562.
    PubMed    


  227. LEAL JL, John T
    Immunotherapy in Advanced NSCLC Without Driver Mutations: Available Therapeutic Alternatives After Progression and Future Treatment Options.
    Clin Lung Cancer. 2022;23:643-658.
    PubMed     Abstract available


  228. ITCHINS M, Ainsworth H, Alexander M, Dean S, et al
    A Multi-Center Real-World Experience of IMpower150 in Oncogene Driven Tumors and CNS Metastases.
    Clin Lung Cancer. 2022;23:702-708.
    PubMed     Abstract available


    November 2022
  229. SHANTZER LB, Dougherty SC, Bolte F, Melson JW, et al
    Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibition in Combination With Chemotherapy: A Brief Report.
    Clin Lung Cancer. 2022 Nov 26:S1525-7304(22)00267.
    PubMed    


  230. DIELEMAN E, van der Woude L, van Os R, van Bockel L, et al
    The Dutch Lung Cancer Audit-Radiotherapy (DLCA-R): Real-World Data on Stage III Non-Small Cell Lung Cancer Patients Treated With Curative Chemoradiation.
    Clin Lung Cancer. 2022 Nov 25:S1525-7304(22)00266.
    PubMed     Abstract available


  231. RAEZ LE, Brice K, Dumais K, Lopez-Cohen A, et al
    Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic Non-Small Cell Lung Cancer (NSCLC).
    Clin Lung Cancer. 2022 Nov 25:S1525-7304(22)00265.
    PubMed     Abstract available


  232. SINGAREDDY A, Flanagan ME, Samson PP, Waqar SN, et al
    Trends in Stage I Lung Cancer.
    Clin Lung Cancer. 2022 Nov 21:S1525-7304(22)00259.
    PubMed     Abstract available


  233. SIMONS EA, Patil T, Camidge DR
    Pregnancy and Pathways to Motherhood in Oncogene-driven Lung Cancer: A Single Institution Experience.
    Clin Lung Cancer. 2022 Nov 11:S1525-7304(22)00255.
    PubMed    


  234. PATEL KG, Corbett RL, Karanjawala ZE, Kelly KA, et al
    A Case of Osimertinib-Induced Eosinophilic Pneumonia.
    Clin Lung Cancer. 2022;23:639-642.
    PubMed    


  235. MACK SJ, Till BM, Huang C, Yang CJ, et al
    Characteristics of High-Volume Lung Segmentectomy Hospitals: A Propensity Score-Matched Analysis.
    Clin Lung Cancer. 2022;23:600-607.
    PubMed     Abstract available


  236. ACKER F, Aguinarte L, Althoff F, Heinzen S, et al
    Study Design and Rationale for the PACE-LUNG Trial: A Multicenter, Single-Arm, Phase II Clinical Trial Evaluating the Efficacy of Additional Chemotherapy for Patients with EGFRm NSCLC with the Continued Presence of Plasma ctDNA EGFRm at Week 3 After S
    Clin Lung Cancer. 2022;23:e473-e477.
    PubMed     Abstract available


  237. GIRARD N, Minchom A, Ou SI, Gadgeel SM, et al
    Comparative Clinical Outcomes Between EGFR Ex20ins and Wildtype NSCLC Treated with Immune Checkpoint Inhibitors.
    Clin Lung Cancer. 2022;23:571-577.
    PubMed     Abstract available


  238. SORSCHER S
    Germline Testing of Patients With Non-small Cell Lung Cancers Demonstrating Incidentally Uncovered BRCA2 Apparent Pathogenic Germline Variants.
    Clin Lung Cancer. 2022;23:e405-e407.
    PubMed     Abstract available


  239. WOO W, Cha YJ, Kim BJ, Moon DH, et al
    Validation Study of New IASLC Histology Grading System in Stage I Non-Mucinous Adenocarcinoma Comparing With Minimally Invasive Adenocarcinoma.
    Clin Lung Cancer. 2022;23:e435-e442.
    PubMed     Abstract available


  240. LIU J, Govindarajan A, Williams TM, Kim J, et al
    An Updated Review on Radiation Treatment Management in Thymus Cancers.
    Clin Lung Cancer. 2022;23:561-570.
    PubMed     Abstract available


  241. RUSS DH, Barta JA, Evans NR, Stapp RT, et al
    Volume Doubling Time of Pulmonary Carcinoid Tumors Measured by Computed Tomography.
    Clin Lung Cancer. 2022;23:e453-e459.
    PubMed     Abstract available


  242. HSU R, Herrmann A, Gaur K, Xia B, et al
    Evaluating Real World Mutational Differences Between Hispanics and Asians in NSCLC at a Large Academic Institution in Los Angeles.
    Clin Lung Cancer. 2022;23:e443-e452.
    PubMed     Abstract available


  243. TRAN JH, Mhango G, Park HS, Marshall DC, et al
    Outcomes Following SBRT vs. IMRT and 3DCRT for Older Patients with Stage IIA Node-Negative Non-Small Cell Lung Cancer > 5 cm.
    Clin Lung Cancer. 2022 Nov 1:S1525-7304(22)00242.
    PubMed     Abstract available


  244. GAZEU A, Aubert M, Pissaloux D, Lantuejoul S, et al
    Small-Cell Lung Cancer Transformation as a Mechanism of Resistance to Pralsetinib in RET-Rearranged Lung Adenocarcinoma: A Case Report.
    Clin Lung Cancer. 2022 Nov 1:S1525-7304(22)00241.
    PubMed     Abstract available


    October 2022
  245. YANG Y, Zhang Y, Zhao D, Li X, et al
    A Novel PRKAR1A::MET Fusion Dramatic Response to Crizotinib in a Patient with Unresectable Lung Cancer.
    Clin Lung Cancer. 2022 Oct 14. pii: S1525-7304(22)00211.
    PubMed    


  246. LIN HM, Wu Y, Yin Y, Niu H, et al
    Real-world ALK Testing Trends in Patients With Advanced Non-Small-Cell Lung Cancer in the United States.
    Clin Lung Cancer. 2022 Oct 13. pii: S1525-7304(22)00213.
    PubMed     Abstract available


  247. KI MS, Kim SY, Kim EY, Jung JY, et al
    Clinical Outcomes and Prognosis of Patients With Interstitial Lung Disease Undergoing Lung Cancer Surgery: A Propensity Score Matching Study.
    Clin Lung Cancer. 2022 Oct 13. pii: S1525-7304(22)00210.
    PubMed     Abstract available


  248. LIU B, Wang Z, Zhao H, Gao S, et al
    The Value of Radiotherapy in Patients With Resectable Stage IIIA Non-Small-Cell Lung Cancer in the Era of Individualized Treatment: A Population-Based Analysis.
    Clin Lung Cancer. 2022 Oct 13:S1525-7304(22)00212.
    PubMed     Abstract available


    September 2022
  249. LI A, Chen HJ, Yang JJ
    Design and Rationale for a Phase II, Randomized, Open-Label, Two-Cohort Multicenter Interventional Study of Osimertinib with or Without Savolitinib in De Novo MET Aberrant, EGFR-Mutant Patients with Advanced Non-Small-Cell Lung Cancer: The FLOWERS Tri
    Clin Lung Cancer. 2022 Sep 30. pii: S1525-7304(22)00205.
    PubMed     Abstract available


  250. KUANG Y, Singh R, Nevo A, Deitz AC, et al
    Incidence of Pneumonitis Among Limited Stage Small Cell Lung Cancer Patients Exposed to Concurrent Chemoradiation: A Systematic Literature Review and Meta-Analysis.
    Clin Lung Cancer. 2022 Sep 26. pii: S1525-7304(22)00204.
    PubMed     Abstract available


  251. PEVNER JL, Tanvetyanon T
    Targeted therapy for lung cancer with paraneoplastic disseminated intravascular coagulation: A case report and pooled analysis.
    Clin Lung Cancer. 2022 Sep 25. pii: S1525-7304(22)00206.
    PubMed    


  252. SCHMID S, Cheng S, Chotai S, Garcia M, et al
    Real-World Treatment Sequencing, Toxicities, Health Utilities, and Survival Outcomes in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2022 Sep 24. pii: S1525-7304(22)00209.
    PubMed     Abstract available


  253. GONUGUNTA AS, Von Itzstein MS, Hsiehchen D, Le T, et al
    Antibiotic Prescriptions in Lung Cancer and Melanoma Populations: Differences With Potential Clinical Implications in the Immunotherapy Era.
    Clin Lung Cancer. 2022 Sep 24. pii: S1525-7304(22)00208.
    PubMed     Abstract available


  254. GUISIER F, Descourt R, Babey H, Huchot E, et al
    Brief Report: First-line Pembrolizumab in Metastatic Non-Small Cell Lung Cancer Habouring MET Exon 14 Skipping Mutation and PD-L1 >/=50% (GFPC 01-20 Study).
    Clin Lung Cancer. 2022 Sep 17. pii: S1525-7304(22)00203.
    PubMed    


  255. SANTOS ES, Rodriguez E
    Treatment Considerations for Patients With Advanced Squamous Cell Carcinoma of the Lung.
    Clin Lung Cancer. 2022;23:457-466.
    PubMed     Abstract available


  256. WU Y, Yin Y, Crossland V, Vincent S, et al
    Survival Outcomes and Treatment Patterns in Patients With NFE2L2 and/or KEAP1 Mutation-Positive Advanced Squamous Cell NSCLC Using a Real-World Clinico-Genomic Database.
    Clin Lung Cancer. 2022;23:487-497.
    PubMed     Abstract available


  257. SHIMODA Y, Shibaki R, Yoshida T, Murakami S, et al
    Concurrent High PD-L1 Expression and CD8(+) Immune Cell Infiltration Predict PD-1 Blockade Efficacy in Advanced EGFR-Mutant NSCLC Patients.
    Clin Lung Cancer. 2022;23:477-486.
    PubMed     Abstract available


  258. SPROAT MR, Hofherr ML, Devarakonda S
    Successful Use of Sotorasib in a Patient With End-Stage Renal Disease on Dialysis With Metastatic Lung Adenocarcinoma: A Case Report.
    Clin Lung Cancer. 2022;23:e339-e341.
    PubMed    


    August 2022
  259. OWEN T, Fung AS
    Combination Intravenous Immune Globulin (IVIG) and High Dose Steroids for Treatment of Immune-Related Myelitis in a Non-Small Cell Lung Cancer Patient Treated With Pembrolizumab and Palliative Radiation Treatment: A Case Report.
    Clin Lung Cancer. 2022 Aug 29. pii: S1525-7304(22)00198.
    PubMed    


  260. MORDANT P MD, PHD, Brosseau S, Milleron B, Santelmo N, et al
    Outcome of Patients With Resected Early-Stage Non-small Cell Lung Cancer and EGFR Mutations: Results From the IFCT Biomarkers France Study.
    Clin Lung Cancer. 2022 Aug 29. pii: S1525-7304(22)00197.
    PubMed     Abstract available


  261. YONESHIMA Y, Morita S, Ando M, Nakamura A, et al
    Nab-Paclitaxel for Previously Treated Advanced Non-Small Cell Lung Cancer: Analysis of Safety and Efficacy for Patients With Renal Impairment.
    Clin Lung Cancer. 2022 Aug 22. pii: S1525-7304(22)00192.
    PubMed     Abstract available


  262. WANG P, Matton L, Kebir F, Kerrou K, et al
    Pralsetinib and Sequential MET Inhibitors to Overcome MET Amplification Resistance in a Patient With a RET Fusion Driven Lung Cancer - Case Report.
    Clin Lung Cancer. 2022 Aug 20. pii: S1525-7304(22)00191.
    PubMed    


  263. YU L, Xu J, Qiao R, Han B, et al
    Pathological Stage N1 Limited-Stage Small-Cell Lung Cancer Patients Can Benefit From Surgical Resection.
    Clin Lung Cancer. 2022 Aug 15. pii: S1525-7304(22)00189.
    PubMed     Abstract available


  264. PENG L, Du B, Cui Y, Luan Q, et al
    (18)F-FDG PET/CT for assessing heterogeneous metabolic response between primary tumor and metastases and prognosis in non-small cell lung cancer.
    Clin Lung Cancer. 2022 Aug 13. pii: S1525-7304(22)00164.
    PubMed     Abstract available


  265. YU NY, DeWees TA, Voss MM, Breen WG, et al
    Cardiopulmonary Toxicity Following Intensity-Modulated Proton Therapy (IMPT) Versus Intensity-Modulated Radiation Therapy (IMRT) for Stage III Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2022 Aug 10. pii: S1525-7304(22)00170.
    PubMed     Abstract available


  266. GUO M, VanderWalde AM, Yu X, Vidal GA, et al
    Immune Checkpoint Inhibitor Rechallenge Safety and Efficacy in Stage IV Non-Small Cell Lung Cancer Patients After Immune-Related Adverse Events.
    Clin Lung Cancer. 2022 Aug 8. pii: S1525-7304(22)00166.
    PubMed     Abstract available


  267. GUO MZ, Murray JC, Ghanem P, Voong KR, et al
    Definitive Chemoradiation and Durvalumab Consolidation for Locally Advanced, Unresectable KRAS-mutated Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2022 Aug 8. pii: S1525-7304(22)00173.
    PubMed     Abstract available


  268. ALNIMER Y, Ali MKM
    Predictors of Secondary Lung Cancer Among Hodgkin Lymphoma Survivors: A Nationwide Analysis.
    Clin Lung Cancer. 2022 Aug 7. pii: S1525-7304(22)00174.
    PubMed     Abstract available


  269. KIM KH, Yoon S, Ahn HK, Lee SY, et al
    A Multicenter Two-arm, Phase II Trial Assessing the Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer (ABLATE, KCSG-LU21-11).
    Clin Lung Cancer. 2022 Aug 7. pii: S1525-7304(22)00169.
    PubMed     Abstract available


  270. MALLER B, Salvatori S, Tanvetyanon T
    Outcomes of Intraocular Metastasis From Lung Cancer in the Era of Targeted Therapy: A Systematic Review and Pooled Analysis.
    Clin Lung Cancer. 2022 Aug 7. pii: S1525-7304(22)00171.
    PubMed     Abstract available


  271. BANG TJ, Hu J, Patil T, Baron AE, et al
    The Effect of Intrathoracic Lesion Location on Initial Tyrosine Kinase Inhibitor Response in Advanced Oncogene-Addicted Non-Small Cell Lung Cancer: A Comparison Between RECIST 1.1 and a Novel Method of Response Assessment (MAX).
    Clin Lung Cancer. 2022 Aug 7. pii: S1525-7304(22)00172.
    PubMed     Abstract available


    July 2022
  272. HUANG CY, Mack S, Grenda TR, Barta JA, et al
    Race is a Risk Factor for the Deferral of Resection and Radiation for Early-Stage Lung Cancer.
    Clin Lung Cancer. 2022 Jul 29. pii: S1525-7304(22)00162.
    PubMed     Abstract available


  273. MAZZASCHI G, Perrone F, Minari R, Verze M, et al
    Therapeutic Outcomes and Clinical Features of Advanced Non-Small Cell Lung Cancer Carrying KRAS Mutations: A Multicenter Real-life Retrospective Study.
    Clin Lung Cancer. 2022 Jul 25. pii: S1525-7304(22)00160.
    PubMed     Abstract available


  274. SHAH M, Marmarelis ME, Mamtani R, Hennessy S, et al
    Association Between Survival and Very High Versus High PD-L1 Expression in Patients Receiving Pembrolizumab as First-line Treatment for Advanced Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2022 Jul 22. pii: S1525-7304(22)00154.
    PubMed     Abstract available


  275. GALLI G, Corsetto PA, Proto C, Lo Russo G, et al
    Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2022 Jul 21. pii: S1525-7304(22)00155.
    PubMed     Abstract available


  276. TSUI DCC, Drusbosky LM, Wienke S, Gao D, et al
    Oncogene Overlap Analysis of Circulating Cell-free Tumor DNA to Explore the Appropriate Criteria for Defining MET Copy Number-Driven Lung Cancer.
    Clin Lung Cancer. 2022 Jul 21. pii: S1525-7304(22)00159.
    PubMed     Abstract available


  277. ZHOU L, Xiong Y, Wang Y, Meng Y, et al
    A Phase IB Trial of Autologous Cytokine-Induced Killer Cells in Combination with Sintilimab, Monoclonal Antibody Against Programmed Cell Death-1, plus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2022 Jul 21. pii: S1525-7304(22)00153.
    PubMed     Abstract available


  278. ARDESHIR-LARIJANI F, Althouse SK, Leal T, Feldman LE, et al
    A Phase II Trial of Atezolizumab Plus Carboplatin Plus Pemetrexed Plus Bevacizumab in the Treatment of Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer: Big Ten Cancer Research Consortium (BTCRC)- LUN 17-139.
    Clin Lung Cancer. 2022 Jul 21. pii: S1525-7304(22)00157.
    PubMed     Abstract available


  279. AHN MJ, Kim HR, Yang JCH, Han JY, et al
    Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study.
    Clin Lung Cancer. 2022 Jul 21. pii: S1525-7304(22)00152.
    PubMed     Abstract available


  280. JOSHI I, Peravali M, Geng X, Rao S, et al
    Impact of Baseline Clinical Biomarkers on Treatment Outcomes in Patients With Advanced NSCLC Receiving First-line Pembrolizumab-Based Therapy.
    Clin Lung Cancer. 2022;23:438-445.
    PubMed     Abstract available


  281. BEHEL V, Chougule A, Noronha V, Patil VM, et al
    Clinical Utility of Liquid Biopsy (Cell-free DNA) Based EGFR Mutation Detection Post treatment Initiation as a Disease Monitoring Tool in Patients With Advanced EGFR-mutant NSCLC.
    Clin Lung Cancer. 2022;23:410-418.
    PubMed     Abstract available


  282. SHINNO Y, Yoshida A, Masuda K, Matsumoto Y, et al
    Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor.
    Clin Lung Cancer. 2022;23:386-392.
    PubMed     Abstract available


  283. MAROONGROGE S, Weissferdt A, Buszek S, Rice DC, et al
    Management of Bronchial Adenoma/Ciliated Muconodular Papillary Tumor with Definitive Stereotactic Body Radiation Therapy (SBRT): A Case Report.
    Clin Lung Cancer. 2022;23:e335-e338.
    PubMed    


    June 2022
  284. VARLOTTO JM, Sun Z, Ky B, Upshaw J, et al
    A Review of Concurrent Chemo/Radiation, Immunotherapy, Radiation Planning, and Biomarkers for Locally Advanced Non-small Cell Lung Cancer and Their Role in the Development of ECOG-ACRIN EA5181.
    Clin Lung Cancer. 2022 Jun 30. pii: S1525-7304(22)00149.
    PubMed     Abstract available


  285. OSTA BE, Carlisle J, Steuer C, Pakkala S, et al
    A Phase 2 Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small-Cell Lung Cancer (NSCLC) who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade.
    Clin Lung Cancer. 2022 Jun 22. pii: S1525-7304(22)00147.
    PubMed     Abstract available


  286. CARDONA AF, Ruiz-Patino A, Recondo G, Martin C, et al
    Mechanisms of Resistance to First-Line Osimertinib in Hispanic Patients With EGFR Mutant Non-Small Cell Lung Cancer (FRESTON-CLICaP).
    Clin Lung Cancer. 2022 Jun 6. pii: S1525-7304(22)00127.
    PubMed     Abstract available


  287. WALIANY S, Wakelee H, Ramchandran K, Das M, et al
    Characterization of ERBB2 (HER2) Alterations in Metastatic Non-small Cell Lung Cancer and Comparison of Outcomes of Different Trastuzumab-based Regimens.
    Clin Lung Cancer. 2022 Jun 3. pii: S1525-7304(22)00128.
    PubMed     Abstract available


  288. VIDETIC GMM, Reddy CA, Woody NM, Stephans KL, et al
    Local Control With Single-Fraction Lung Stereotactic Body Radiotherapy is not influenced by Non-Small Cell Lung Cancer Histologic Subtype.
    Clin Lung Cancer. 2022 Jun 3. pii: S1525-7304(22)00129.
    PubMed     Abstract available


  289. VEILLON R, Sakai H, Le X, Felip E, et al
    Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management.
    Clin Lung Cancer. 2022;23:320-332.
    PubMed     Abstract available


  290. COSTA BA, Maraveyas A, Wilkoff MH, Correia GSC, et al
    Primary Pulmonary NUT Carcinoma: Case Illustration and Updated Review of Literature.
    Clin Lung Cancer. 2022;23:e296-e300.
    PubMed    


  291. CAMIDGE DR, Moran T, Demedts I, Grosch H, et al
    A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib.
    Clin Lung Cancer. 2022;23:300-310.
    PubMed     Abstract available


  292. ANDRAOS TY, Halmos B, Cheng H, Huntzinger C, et al
    Disease Burden on PET Predicts Outcomes for Advanced NSCLC Patients Treated with First-Line Immunotherapy.
    Clin Lung Cancer. 2022;23:291-299.
    PubMed     Abstract available


  293. GUO Y, Wei L, Patel SH, Lopez G, et al
    Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy.
    Clin Lung Cancer. 2022;23:345-355.
    PubMed     Abstract available


  294. FEDERICO AD, Gelsomino F, De Biase D, Ardizzoni A, et al
    Should We Test Cancer Susceptibility Genes in Routinely Used Multigene Panels? A Case of Synchronous Lung Adenocarcinoma and Breast Cancer Associated With Germline CHEK2 Mutation.
    Clin Lung Cancer. 2022;23:e283-e284.
    PubMed    


    May 2022
  295. MORENO V, Roda D, Pikiel J, Trigo J, et al
    Safety and Efficacy of Dostarlimab in Patients With Recurrent/Advanced Non-small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial.
    Clin Lung Cancer. 2022 May 23. pii: S1525-7304(22)00115.
    PubMed     Abstract available


  296. SIRGI Y, Krochmal R, Fleury CM, Holmes M, et al
    Pembrolizumab-Associated Cutaneous and Pulmonary Sarcoidosis in Non-Small Cell Lung Cancer Treatment.
    Clin Lung Cancer. 2022 May 20. pii: S1525-7304(22)00107.
    PubMed     Abstract available


  297. CUCCHIARA F, Petrini I, Passaro A, Attili I, et al
    Gene network Analysis Defines a Subgroup of Small Cell Lung Cancer patients With Short Survival.
    Clin Lung Cancer. 2022 May 20. pii: S1525-7304(22)00108.
    PubMed     Abstract available


  298. NAGATA S, Hamaji M, Ozasa H, Yamada Y, et al
    Salvage Surgery After Immune Checkpoint Inhibitors for Advanced Non-Small Cell Lung Cancer: Potential Association Between Immune-Related Adverse Events and Longer Survival.
    Clin Lung Cancer. 2022 May 11. pii: S1525-7304(22)00098.
    PubMed    


  299. ZHU F, Wang H, Ashamalla H
    The Significance of Lymph Node Ratio and Total Lymph Nodes Examined in Determining the Indications of Adjuvant Radiation in pN2 Non-small Cell Lung Cancer.
    Clin Lung Cancer. 2022 May 11. pii: S1525-7304(22)00102.
    PubMed     Abstract available


  300. RIUDAVETS M, Lamberts V, Vasseur D, Auclin E, et al
    Clinical Utility and Outcomes Impact of Crystal Digital PCR of Sensitizing and Resistance EGFR Mutations in Patients With Advanced Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2022 May 11. pii: S1525-7304(22)00105.
    PubMed     Abstract available


  301. LIU SM, Yan HH, Wei XW, Lu C, et al
    Biomarker-Driven Studies With Multi-targets and Multi-drugs by Next-Generation Sequencing for Patients With Non-Small-Cell Lung Cancer: An Open-Label, Multi-center, Phase II Adaptive Umbrella Trial and a Real-World Observational Study (CTONG1702&CTONG
    Clin Lung Cancer. 2022 May 11. pii: S1525-7304(22)00101.
    PubMed     Abstract available


  302. BIRONZO P, Primo L, Novello S, Righi L, et al
    Clinical-Molecular Prospective Cohort Study in Non-Small Cell Lung Cancer (PROMOLE study): A Comprehensive Approach to Identify New Predictive Markers of Pharmacological Response.
    Clin Lung Cancer. 2022 May 11. pii: S1525-7304(22)00100.
    PubMed     Abstract available


  303. FUKUSHIMA T, Oyamada Y, Ikemura S, Nukaga S, et al
    Real-world clinical practice for advanced non-small-cell lung cancer in the very elderly: A retrospective multicenter analysis.
    Clin Lung Cancer. 2022 May 11. pii: S1525-7304(22)00099.
    PubMed     Abstract available


  304. SCHNEIDER CS, Hatic H, Das D, Cardan RA, et al
    Patterns of Failure and Optimal Treatment Paradigm for Large, Inoperable, Node-Negative Non-small Cell Lung Cancer.
    Clin Lung Cancer. 2022 May 11. pii: S1525-7304(22)00103.
    PubMed     Abstract available


  305. SCHMID S, Minnella EM, Pilon Y, Rokah M, et al
    Neoadjuvant Prehabilitation Therapy for Locally Advanced Non-Small-Cell Lung Cancer: Optimizing Outcomes Throughout the Trajectory of Care.
    Clin Lung Cancer. 2022 May 11. pii: S1525-7304(22)00097.
    PubMed     Abstract available


  306. ZHOU Q, Wang M, Zhang H, Hong Q, et al
    Safety and Efficacy of Epitinib for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases: Open-Label Multicentre Dose-Expansion Phase Ib Study.
    Clin Lung Cancer. 2022 May 7. pii: S1525-7304(22)00037.
    PubMed     Abstract available


  307. MAYNE NR, Bajaj SS, Powell J, Elser HC, et al
    Extended Delay to Treatment for Stage III-IV Non-Small-Cell Lung Cancer and Survival: Balancing Risks During the COVID-19 Pandemic.
    Clin Lung Cancer. 2022 May 5. pii: S1525-7304(22)00069.
    PubMed     Abstract available


  308. SODJI QH, Harris JP, Quon A, Modlin LA, et al
    Detection of Recurrence After Thoracic Stereotactic Ablative Radiotherapy Using FDG-PET-CT.
    Clin Lung Cancer. 2022;23:282-289.
    PubMed     Abstract available


  309. WHITE MN, Piper-Vallillo AJ, Gardner RM, Cunanan K, et al
    Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on Osimertinib.
    Clin Lung Cancer. 2022;23:e210-e221.
    PubMed     Abstract available


  310. FUJINO T, Suda K, Sakai K, Murakami I, et al
    Intra-tumor and Inter-tumor Heterogeneity in MET Exon 14 Skipping Mutations and Co-mutations in Pulmonary Pleomorphic Carcinomas.
    Clin Lung Cancer. 2022;23:e185-e195.
    PubMed     Abstract available


  311. BELLUOMINI L, Dionisi V, Palmerio S, Vincenzi S, et al
    Study Design and Rationale for Espera Trial: A Multicentre, Randomized, Phase II Clinical Trial Evaluating the Potential Efficacy of Adding SBRT to Pembrolizumab-Pemetrexed Maintenance in Responsive or Stable Advanced Non-Squamous NSCLC After Chemo-Im
    Clin Lung Cancer. 2022;23:e269-e272.
    PubMed     Abstract available


  312. REMON J, Girard N, Novello S, de Castro J, et al
    PECATI: A Multicentric, Open-Label, Single-Arm Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab and Lenvatinib in Pretreated B3-Thymoma and Thymic Carcinoma Patients.
    Clin Lung Cancer. 2022;23:e243-e246.
    PubMed     Abstract available


  313. YONEDA T, Sone T, Koba H, Shibata K, et al
    Long-Term Survival of Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor Monotherapy in Real-World Settings.
    Clin Lung Cancer. 2022 May 1. pii: S1525-7304(22)00055.
    PubMed     Abstract available


    April 2022
  314. SCHILD SE, Wang X, Bestvina CM, Williams T, et al
    Alliance A082002 -a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung cancer.
    Clin Lung Cancer. 2022 Apr 30. pii: S1525-7304(22)00065.
    PubMed     Abstract available


  315. RIMNER A, Lai WV, Califano R, Jabbour SK, et al
    Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer.
    Clin Lung Cancer. 2022 Apr 29. pii: S1525-7304(22)00058.
    PubMed     Abstract available


  316. ABDELGHANY K, Macaulay R, Tang Z, Tanvetyanon T, et al
    Pulmonary Ewing Sarcoma Mimicking Small Cell Lung Cancer.
    Clin Lung Cancer. 2022 Apr 29. pii: S1525-7304(22)00061.
    PubMed    


  317. MERKHOFER CM, Eastman B, Densmore I, Halasz LM, et al
    Systemic Treatment Patterns and Outcomes in Patients With EGFR Mutated Non-small Cell Lung Cancer and Leptomeningeal Disease.
    Clin Lung Cancer. 2022 Apr 29. pii: S1525-7304(22)00056.
    PubMed     Abstract available


  318. ROBINSON EM, Liu BY, Sigel K, Yin C, et al
    Impact of Comorbidities on Lung Cancer Screening Evaluation.
    Clin Lung Cancer. 2022 Apr 29. pii: S1525-7304(22)00054.
    PubMed     Abstract available


  319. MIKAMI N, Takeda A, Hashimoto A, Takeda T, et al
    CT Findings and Treatment Outcomes of Ground-Glass Opacity Predominant Lung Cancer After Stereotactic Body Radiotherapy.
    Clin Lung Cancer. 2022 Apr 29. pii: S1525-7304(22)00064.
    PubMed     Abstract available


  320. MAJEED H, Zhu H, Williams SA, Hamann HA, et al
    Prevalence And Impact of Medical Comorbidities in A Real-World Lung Cancer Screening Population.
    Clin Lung Cancer. 2022 Apr 29. pii: S1525-7304(22)00057.
    PubMed     Abstract available


  321. CAMIDGE DR, Mandair D, Morgan R, Amini A, et al
    Quantifying The Medical Impact of A Missed Diagnosis of Non-Small Cell Lung Cancer on Chest Imaging.
    Clin Lung Cancer. 2022 Apr 29. pii: S1525-7304(22)00059.
    PubMed     Abstract available


  322. JABBOUR SK, Cho BC, Bria E, Kato T, et al
    Rationale and Design of the Phase III KEYLYNK-012 Study of Pembrolizumab and Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Stage III Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2022 Apr 29. pii: S1525-7304(22)00066.
    PubMed     Abstract available


  323. HANDA Y, Tsutani Y, Mimae T, Miyata Y, et al
    A Multicenter Study of Complex Segmentectomy Versus Wedge Resection in Clinical Stage 0-IA Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2022 Apr 27. pii: S1525-7304(21)00267.
    PubMed     Abstract available


  324. ZHANG C, Li F, Li J, Xu Y, et al
    Corrigendum to "Docetaxel downregulates PD-1 expression via STAT3 in Tlymphocytes" [Clinical Lung Cancer 19 (2018) e675-e683].
    Clin Lung Cancer. 2022 Apr 15. pii: S1525-7304(22)00040.
    PubMed    


    March 2022
  325. CIUNCI CA, Reibel JB, Evans TL, Mick R, et al
    Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non-squamous Non-small Cell Lung Cancer After Progression on Platinum and Pemetrexed.
    Clin Lung Cancer. 2022 Mar 14. pii: S1525-7304(22)00034.
    PubMed     Abstract available


  326. HOLTZMAN L, Moskovitz M, Urban D, Nechushtan H, et al
    dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score >/=50.
    Clin Lung Cancer. 2022;23:122-134.
    PubMed     Abstract available


  327. PATHAK R, Salgia R
    Near-Complete Response to Combined Pembrolizumab and Platinum-Doublet in a Patient With STK11/KRAS Mutated Advanced Lung Adenocarcinoma.
    Clin Lung Cancer. 2022;23:e137-e139.
    PubMed    


  328. SHAH MP, Aredo JV, Padda SK, Ramchandran KJ, et al
    EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy.
    Clin Lung Cancer. 2022;23:e148-e153.
    PubMed     Abstract available


  329. ASEMOTA N, Saftic I, Tsitsias T, King J, et al
    Quality of Life in Octogenarians After Lung Resection Compared to Younger Patients.
    Clin Lung Cancer. 2022;23:e118-e130.
    PubMed     Abstract available


  330. XU J, He T, Wu Y, Cao J, et al
    VATS Versus Open Lobectomy in Pathological T1 SCLC: A Multi-Center Retrospective Analysis.
    Clin Lung Cancer. 2022;23:170-176.
    PubMed     Abstract available


  331. ZHANG S, Li S, Liu J, Yang C, et al
    Comparative Efficacy and Safety of TKIs Alone or in Combination With Antiangiogenic Agents in Advanced EGFR-Mutated NSCLC as the First-Line Treatment: A Systematic Review and Meta-Analysis.
    Clin Lung Cancer. 2022;23:159-169.
    PubMed     Abstract available


    February 2022
  332. PAYNE RG, Anker CJ, Sprague BL, No HJ, et al
    Active Surveillance for Early Stage Lung Cancer.
    Clin Lung Cancer. 2022 Feb 12. pii: S1525-7304(22)00012.
    PubMed     Abstract available


  333. JAZIEH AR, Saglam EK, Onal HC, Abdelkader Y, et al
    Real-world Treatment Patterns and Outcomes in Stage III Non-small Cell Lung Cancer: Middle East and Africa - KINDLE Study.
    Clin Lung Cancer. 2022 Feb 11. pii: S1525-7304(22)00016.
    PubMed     Abstract available


  334. HARRIS JP, Fujimoto DK, Nagasaka M, Ku E, et al
    Controversies in Lung Cancer: Heterogeneity in Treatment Recommendations for Stage III NSCLC According to Disease Burden and Oncogenic Driver Alterations.
    Clin Lung Cancer. 2022 Feb 10. pii: S1525-7304(22)00015.
    PubMed     Abstract available


  335. KAUFFMANN-GUERRERO D, Walter J, Kovacs J, Sellmer L, et al
    The Role of Thoracic Surgery in Small Cell Lung Cancer - A Large Longitudinal Analysis (2002-2015) Based on Real-World Data.
    Clin Lung Cancer. 2022 Feb 4. pii: S1525-7304(22)00009.
    PubMed     Abstract available


  336. CORTOT A, Le X, Smit E, Viteri S, et al
    Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review.
    Clin Lung Cancer. 2022 Feb 4. pii: S1525-7304(22)00013.
    PubMed     Abstract available


  337. GOVINDAN R, Lind M, Insa A, Khan SA, et al
    Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2022 Feb 4. pii: S1525-7304(22)00011.
    PubMed     Abstract available


  338. IZANO MA, Tran N, Fu A, Toland L, et al
    Implementing Real-World RECIST-based Tumor Response Assessment in Patients With Metastatic Non-small Cell Lung Cancer.
    Clin Lung Cancer. 2022 Feb 3. pii: S1525-7304(22)00014.
    PubMed     Abstract available


    January 2022
  339. ALTAN M, Singhi EK, Worst M, Carter BW, et al
    Clinical Effectiveness and Safety of Anti-PD-(L)1 Therapy Among Older Adults With Advanced Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2022 Jan 31. pii: S1525-7304(22)00006.
    PubMed     Abstract available


  340. MARMARELIS ME, Yang YX, Hwang WT, Mamtani R, et al
    Platinum Re-Exposure as a Non-Small Cell Lung Cancer (NSCLC) Treatment Strategy in the Age of Immunotherapy.
    Clin Lung Cancer. 2022 Jan 10. pii: S1525-7304(22)00005.
    PubMed     Abstract available


  341. STOKES WA, Xiong N, Liu Y, Higgins KA, et al
    Association of Operability With Post-Treatment Mortality in Early-Stage Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2022 Jan 10. pii: S1525-7304(22)00007.
    PubMed     Abstract available


  342. HAYASHI H, Nadal E, Gray JE, Ardizzoni A, et al
    Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations.
    Clin Lung Cancer. 2022;23:e69-e82.
    PubMed     Abstract available


  343. LI Y, Wang K, Tian P, Li W, et al
    Acquired MET-DSTN Fusion Mediated Resistance to EGFR-TKIs in Lung Adenocarcinoma and Responded to Crizotinib Plus Gefitinib: A Case Report.
    Clin Lung Cancer. 2022;23:e83-e86.
    PubMed    


  344. HIRSCH FR, Walker J, Higgs BW, Cooper ZA, et al
    The Combiome Hypothesis: Selecting Optimal Treatment for Cancer Patients.
    Clin Lung Cancer. 2022;23:1-13.
    PubMed     Abstract available


  345. LECLAIR JN, Merl MY, Cohenuram M, Luon D, et al
    Real-World Incidence of Pneumonitis in Patients Receiving Durvalumab.
    Clin Lung Cancer. 2022;23:34-42.
    PubMed     Abstract available


  346. SCHMID S, Zhan L, Dietrich K, Khan K, et al
    Treatment Patterns and Outcomes of Patients With Advanced Pleural Mesothelioma at an Academic Referral Centre.
    Clin Lung Cancer. 2022;23:e43-e53.
    PubMed     Abstract available


  347. CAREY ET, Ferreira V, Shum E, Zhou F, et al
    The Common Thread: A Case of Synchronous Lung Cancers and a Germline CHEK2 Mutation.
    Clin Lung Cancer. 2022;23:e1-e4.
    PubMed     Abstract available


    December 2021
  348. ZHANG L, Yang X, Ming Z, Shi J, et al
    Molecular Characteristics of the Uncommon EGFR Exon 21 T854A Mutation and Response to Osimertinib in Patients With Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2021 Dec 24. pii: S1525-7304(21)00304.
    PubMed     Abstract available


  349. HIJMERING-KAPPELLE LBM, Hiltermann TJN, Bensch F
    Safety and Efficacy of Extended Interval Dosing for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer During the COVID-19 Pandemic.
    Clin Lung Cancer. 2021 Dec 24. pii: S1525-7304(21)00305.
    PubMed     Abstract available


  350. LOGTENBERG ME, Tomlow B, Kastelijn EA, Schramel FMNH, et al
    Benefit of Concurrent Versus Sequential Chemoradiotherapy in Elderly Patients With Stage III Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2021 Dec 17. pii: S1525-7304(21)00291.
    PubMed     Abstract available


  351. AKHTAR A, Sosa E, Castro S, Sur M, et al
    A Lung Cancer Screening Education Program Impacts both Referral Rates and Provider and Medical Assistant Knowledge at Two Federally Qualified Health Centers.
    Clin Lung Cancer. 2021 Dec 12. pii: S1525-7304(21)00289.
    PubMed     Abstract available


  352. YAGA M, Shiroyama T, Hirata H, Oya K, et al
    Lipoid Pneumonia After Pembrolizumab Treatment for Advanced Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2021 Dec 10. pii: S1525-7304(21)00290.
    PubMed    


  353. KEE W, Ng KYY, Lee JJX, Tan DSW, et al
    Myasthenia Gravis and Myocarditis After Administration of Pembrolizumab in a Patient With Metastatic Non-small Cell Lung Cancer and Resected Thymoma.
    Clin Lung Cancer. 2021 Dec 10. pii: S1525-7304(21)00288.
    PubMed    


    November 2021
  354. GANESH A, Katipally R, Pasquinelli M, Feldman L, et al
    Increased Disparities in Patients Diagnosed with Metastatic Lung Cancer Following Lung CT Screening in the United States.
    Clin Lung Cancer. 2021 Nov 25. pii: S1525-7304(21)00287.
    PubMed     Abstract available


  355. HEYNEMANN S, Yu H, Churilov L, Rivalland G, et al
    NaPi2b expression in a large surgical Non-Small Cell Lung Cancer (NSCLC) cohort.
    Clin Lung Cancer. 2021 Nov 16. pii: S1525-7304(21)00281.
    PubMed     Abstract available


  356. ALDIN MK, Qi L, Zhou X, Kahn LA, et al
    Detection of second primary lung cancers on surveillance imaging following stereotactic ablative radiotherapy for non-small cell lung cancer.
    Clin Lung Cancer. 2021 Nov 11. pii: S1525-7304(21)00280.
    PubMed     Abstract available


  357. CATANIA C, Muthusamy B, Spitaleri G, Del Signore E, et al
    The new era of immune checkpoint inhibition and target therapy in early-stage non-small cell lung cancer. A review of the literature.
    Clin Lung Cancer. 2021 Nov 11. pii: S1525-7304(21)00279.
    PubMed     Abstract available


  358. HOCHMAIR MJ, Illini O, Prosch H, Krenbek D, et al
    Complete Remission to Afatinib in a Patient Harboring a Novel Epidermal Growth Factor Mutation in De Novo Small-Cell Lung Cancer: A Case Report: Clinical Lung Cancer.
    Clin Lung Cancer. 2021 Nov 10. pii: S1525-7304(21)00277.
    PubMed    


  359. SUVEG K, Le Pechoux C, Faivre-Finn C, Putora PM, et al
    Role of Postoperative Radiotherapy in the Management for Resected NSCLC - Decision Criteria in Clinical Routine Pre- and Post-LungART.
    Clin Lung Cancer. 2021;22:579-586.
    PubMed     Abstract available


  360. WATERHOUSE DM, Tseng WY, Espirito JL, Robert NJ, et al
    Understanding Contemporary Molecular Biomarker Testing Rates and Trends for Metastatic NSCLC Among Community Oncologists.
    Clin Lung Cancer. 2021;22:e901-e910.
    PubMed     Abstract available


  361. WANG B, Hamal P, Sun K, Bhuva MS, et al
    Clinical Value and Pathologic Basis of Cystic Airspace Within Subsolid Nodules Confirmed as Lung Adenocarcinomas by Surgery.
    Clin Lung Cancer. 2021;22:e881-e888.
    PubMed     Abstract available


  362. WANG CY, Hsia JY, Li CH, Ho CC, et al
    Lung Adenocarcinoma With Primary LIMD1-BRAF Fusion Treated With MEK Inhibitor: A Case Report.
    Clin Lung Cancer. 2021;22:e878-e880.
    PubMed    


  363. CLEMENT MS, Ebert EBF, Meldgaard P, Sorensen BS, et al
    Co-occurring MET Amplification Predicts Inferior Clinical Response to First-Line Erlotinib in Advanced Stage EGFR-Mutated NSCLC Patients.
    Clin Lung Cancer. 2021;22:e870-e877.
    PubMed     Abstract available


  364. YU J, Du Y, Mekhail T, Socinski MA, et al
    Adverse Overall Survival Impact of PD-L1 Positivity in Patients With KRAS G12C Mutation Is Abolished by the Immunotherapy.
    Clin Lung Cancer. 2021;22:e856-e858.
    PubMed    


  365. JI J, Mitra A, Camidge DR, Riess JW, et al
    Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and Crizotinib.
    Clin Lung Cancer. 2021;22:e851-e855.
    PubMed    


  366. FURUTA H, Kato S, Masago K, Hida T, et al
    Palmoplantar Pustulosis Caused by Immune-Checkpoint Inhibitors.
    Clin Lung Cancer. 2021;22:e829-e832.
    PubMed    


  367. SHIGENOBU T, Takahashi Y, Masugi Y, Hanawa R, et al
    Micropapillary Predominance Is a Risk Factor for Brain Metastasis in Resected Lung Adenocarcinoma.
    Clin Lung Cancer. 2021;22:e820-e828.
    PubMed     Abstract available


  368. CECCHI C, Mariniello A, Carnio S, Delcuratolo MD, et al
    Black Hairy Tongue After Immune Checkpoint Inhibitors in NSCLC: A Case Report and Review of the Literature.
    Clin Lung Cancer. 2021;22:e804-e807.
    PubMed    


    October 2021
  369. XIAOBING L, Meipan Y, Pengfei X, Yue Z, et al
    Bronchial Artery Chemoembolization for Hemoptysis in Advanced Primary Lung Cancer.
    Clin Lung Cancer. 2021 Oct 29. pii: S1525-7304(21)00272.
    PubMed     Abstract available


  370. SHIRAISHI Y, Hakozaki T, Nomura S, Kataoka T, et al
    A Multicenter, Randomized Phase III Study Comparing Platinum Combination Chemotherapy Plus Pembrolizumab With Platinum Combination Chemotherapy Plus Nivolumab and Ipilimumab for Treatment-Naive Advanced Non-Small Cell Lung Cancer Without Driver Gene A
    Clin Lung Cancer. 2021 Oct 25. pii: S1525-7304(21)00271.
    PubMed     Abstract available


  371. GARON EB, Peterson P, Rizzo MT, Kim JS, et al
    Overall Survival and Safety With Pemetrexed/Platinum +/- Anti-VEGF Followed by Pemetrexed +/- Anti-VEGF Maintenance in Advanced Nonsquamous Non-Small-Cell Lung Cancer: A Pooled Analysis of 4 Randomized Studies.
    Clin Lung Cancer. 2021 Oct 25. pii: S1525-7304(21)00274.
    PubMed     Abstract available


  372. SONODA D, Matsuura Y, Kondo Y, Ichinose J, et al
    A Reasonable Definition of Oligo-Recurrence in Non-Small-Cell Lung Cancer.
    Clin Lung Cancer. 2021 Oct 25. pii: S1525-7304(21)00276.
    PubMed     Abstract available


  373. DOYEN J, Besse B, Texier M, Bonnet N, et al
    PD-1 iNhibitor and chemotherapy with concurrent IRradiation at VAried tumor sites in advanced Non-small cell lung cAncer: the Prospective Randomized Phase 3 NIRVANA-Lung Trial.
    Clin Lung Cancer. 2021 Oct 24. pii: S1525-7304(21)00269.
    PubMed     Abstract available


  374. HARATAKE N, Hayashi H, Shimokawa M, Nakano Y, et al
    Phase III Clinical Trial for the Combination of Erlotinib Plus Ramucirumab Compared With Osimertinib in Previously Untreated Advanced or Recurrent Non-Small Cell Lung Cancer Positive for the L858R Mutation of EGFR: REVOL858R (WJOG14420L).
    Clin Lung Cancer. 2021 Oct 24. pii: S1525-7304(21)00270.
    PubMed     Abstract available


  375. LI J, Wang Y, Li J, Cao S, et al
    Meta-analysis of Lobectomy and Sublobar Resection for Stage I Non-small Cell Lung Cancer With Spread Through Air Spaces.
    Clin Lung Cancer. 2021 Oct 23. pii: S1525-7304(21)00268.
    PubMed     Abstract available


  376. HELLYER JA, White MN, Gardner RM, Cunanan K, et al
    Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer.
    Clin Lung Cancer. 2021 Oct 21. pii: S1525-7304(21)00245.
    PubMed     Abstract available


  377. NAGASAKA M, Singh V, Baca Y, Sukari A, et al
    The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer.
    Clin Lung Cancer. 2021 Oct 18. pii: S1525-7304(21)00244.
    PubMed     Abstract available


  378. HIRSCH FR, Redman MW, Moon J, Agustoni F, et al
    EGFR High Copy Number Together With High EGFR Protein Expression Predicts Improved Outcome for Cetuximab-based Therapy in Squamous Cell Lung Cancer: Analysis From SWOG S0819, a Phase III Trial of Chemotherapy With or Without Cetuximab in Advanced NSCL
    Clin Lung Cancer. 2021 Oct 10. pii: S1525-7304(21)00263.
    PubMed     Abstract available


  379. SUDA K, Ohara S, Fujino T, Hamada A, et al
    Frequent EGFR Mutations and Better Prognosis in Positron Emission Tomography-Negative, Solid-Type Lung Cancer.
    Clin Lung Cancer. 2021 Oct 10. pii: S1525-7304(21)00264.
    PubMed     Abstract available


  380. PAGE RD, Drusbosky LM, Dada H, Raymond VM, et al
    Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2021 Oct 10. pii: S1525-7304(21)00262.
    PubMed     Abstract available


  381. LELEU O, Basille D, Auquier M, Clarot C, et al
    Results of Second Round Lung Cancer Screening by Low-Dose CT scan - French Cohort Study (DEP-KP80).
    Clin Lung Cancer. 2021 Oct 10. pii: S1525-7304(21)00261.
    PubMed     Abstract available


  382. HEYMACH JV, Mitsudomi T, Harpole D, Aperghis M, et al
    Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab+Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN
    Clin Lung Cancer. 2021 Oct 10. pii: S1525-7304(21)00265.
    PubMed     Abstract available


  383. YAMASAKI N, Kim YH, Iwatsubo S, Nishimura Y, et al
    Role of Postoperative Radiotherapy in Patients With Completely Resected pIIIA-N2 Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2021 Oct 2. pii: S1525-7304(21)00249.
    PubMed    


    September 2021
  384. KUEHNE N, Hueniken K, Xu M, Shakik S, et al
    Longitudinal Assessment of Health Utility Scores, Symptoms and Toxicities in Patients with Small Cell Lung Cancer Using Real World Data.
    Clin Lung Cancer. 2021 Sep 25. pii: S1525-7304(21)00247.
    PubMed     Abstract available


  385. NAKAO M, Saji H, Mun M, Nakamura H, et al
    Prognostic Impact of Mediastinal Lymph Node Dissection in Octogenarians With Lung Cancer: JACS1303.
    Clin Lung Cancer. 2021 Sep 24. pii: S1525-7304(21)00248.
    PubMed     Abstract available


  386. TU HY, Li YS, Bai XY, Sun YL, et al
    Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets.
    Clin Lung Cancer. 2021 Sep 20. pii: S1525-7304(21)00242.
    PubMed     Abstract available


  387. SAKAGUCHI T, Kokubo Y, Furuhashi K, Nakamura Y, et al
    An Extensive-stage Small-cell Lung Cancer Case With Preexisting Lambert-Eaton Myasthenic Syndrome Successfully Treated With an Immune Checkpoint Inhibitor.
    Clin Lung Cancer. 2021 Sep 17. pii: S1525-7304(21)00241.
    PubMed    


  388. HAO Z, Sekkath Veedu J
    Current Strategies for Extensive Stage Small Cell Lung Cancer Beyond First-line Therapy.
    Clin Lung Cancer. 2021 Sep 17. pii: S1525-7304(21)00243.
    PubMed     Abstract available


  389. LI X, Sun J, Wang L
    NF1-Mutant Cancer and Immune Checkpoint Inhibitors: A Large Database Analysis.
    Clin Lung Cancer. 2021;22:480-481.
    PubMed    


  390. ALTAN M, Patel AB
    Management of Cutaneous Immunotherapy Toxicities.
    Clin Lung Cancer. 2021;22:e783.
    PubMed    


  391. HUANG WL, Liu YW
    The Role of Stereotactic Body Radiation Therapy for Pulmonary Carcinosarcoma.
    Clin Lung Cancer. 2021;22:e684-e685.
    PubMed    


  392. NASSER A, Baird A, Saint-Pierre MD, Amjadi K, et al
    Three Decades of Malignant Pleural Mesothelioma: An Academic Center Experience.
    Clin Lung Cancer. 2021;22:441-448.
    PubMed     Abstract available


  393. VEKENS K, Everaert H, Neyns B, Ilsen B, et al
    The Value of (18)F-FDG PET/CT in Predicting the Response to PD-1 Blocking Immunotherapy in Advanced NSCLC Patients with High-Level PD-L1 Expression.
    Clin Lung Cancer. 2021;22:432-440.
    PubMed     Abstract available


  394. LIM JU
    Management of Oligometastasis and Oligoprogression in Patients with Epidermal Growth Factor Receptor Mutation-Positive NSCLC in the Era of Third-Generation Tyrosine Kinase Inhibitors.
    Clin Lung Cancer. 2021;22:e786-e792.
    PubMed     Abstract available


  395. TAKAO T, Tanaka K, Shiraishi Y, Ota K, et al
    Osimertinib-induced Syndrome of Inappropriate Secretion of Antidiuretic Hormone.
    Clin Lung Cancer. 2021;22:e784-e785.
    PubMed    


  396. GILES AE, Teferi Y, Kidane B, Bayaraa B, et al
    Lung Resection Without Tissue Diagnosis: A Pragmatic Perspective on the Indeterminate Pulmonary Nodule.
    Clin Lung Cancer. 2021;22:e774-e781.
    PubMed     Abstract available


  397. PERNA M, Scotti V, Ciammella P, Borghetti P, et al
    The NIPRO Study: An Observational, Retrospective, Multicenter Study on the Safety of the Radiotherapy and Immunotherapy Combination for Advanced-Stage NSCLC.
    Clin Lung Cancer. 2021;22:e767-e773.
    PubMed     Abstract available


  398. LEONETTI A, Minari R, Boni L, Gnetti L, et al
    Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial.
    Clin Lung Cancer. 2021;22:473-477.
    PubMed     Abstract available


  399. LIN G, Liu Y, Li H, Chen S, et al
    Emergence of NOTCH2-NTRK1 After Osimertinib in a Patient With Lung Adenocarcinoma With Neuroendocrine Differentiation.
    Clin Lung Cancer. 2021;22:e712-e715.
    PubMed    


  400. HARADA G, Amano MT, Antonacio FF, Behar MH, et al
    Dramatic Response to Pembrolizumab Monotherapy in a Patient With ARID1A-Mutant Lung Adenocarcinoma: Case Report.
    Clin Lung Cancer. 2021;22:e708-e711.
    PubMed     Abstract available


  401. FROST N, Kollmeier J, Misch D, Vollbrecht C, et al
    Pembrolizumab as First-Line Palliative Therapy in PD-L1 Overexpressing (>/= 50%) NSCLC: Real-world Results with Special Focus on PS >/= 2, Brain Metastases, and Steroids.
    Clin Lung Cancer. 2021;22:411-422.
    PubMed     Abstract available


  402. ZHANG Y, Wang H, Wang X, Li S, et al
    Precision Treatment of Advanced Lung Adenocarcinoma With Coexisting EGFR, ALK, and ROS1 Mutations: A Case Report.
    Clin Lung Cancer. 2021;22:e699-e702.
    PubMed    


  403. WADDINGTON T, Mambetsariev I, Pharaon R, Fricke J, et al
    Therapeutic Potential of Olaparib in Combination With Pembrolizumab in a Young Patient With a Maternally Inherited BRCA2 Germline Variant: A Research Report.
    Clin Lung Cancer. 2021;22:e703-e707.
    PubMed    


  404. DOUBRE H, Fraboulet S, Longchampt E, Damotte D, et al
    ALK Rearrangement in Lung Neuroendocrine Neoplasms: Case Series of Non-Asian Patients With Response to ALK Inhibitors.
    Clin Lung Cancer. 2021;22:e686-e690.
    PubMed    


  405. AREDO JV, Diehn M, Berry GJ, Wakelee HA, et al
    Targeted Treatment of Multiple Primary Lung Cancers Harboring Distinct EGFR or RET Alterations: A Case Report.
    Clin Lung Cancer. 2021;22:e673-e677.
    PubMed    


  406. DAVIS A, Mahar A, Wong K, Barnet M, et al
    Prolonged Disease Control on Nivolumab for Primary Pulmonary NUT Carcinoma.
    Clin Lung Cancer. 2021;22:e665-e667.
    PubMed    


    August 2021
  407. MYNARD N, Saxena A, Mavracick A, Port J, et al
    Lung Cancer Stage Shift as a Result of COVID-19 Lockdowns in New York City, a Brief Report.
    Clin Lung Cancer. 2021 Aug 29. pii: S1525-7304(21)00214.
    PubMed     Abstract available


  408. JIN Y, Xue Q, Shen X, Zheng Q, et al
    PD-L1 Expression and Comprehensive Molecular Profiling Predict Survival in Nonsmall Cell Lung Cancer: A Real-World Study of a Large Chinese Cohort.
    Clin Lung Cancer. 2021 Aug 28. pii: S1525-7304(21)00213.
    PubMed     Abstract available


  409. SEITLINGER J, Prieto M, Guerrera F, Streit A, et al
    Neutrophil-to-lymphocyte ratio is correlated to driver gene mutations in surgically-resected non-small cell lung cancer and its post-operative evolution impacts outcomes.
    Clin Lung Cancer. 2021 Aug 22. pii: S1525-7304(21)00205.
    PubMed     Abstract available


  410. WOODARD GA, Kratz JR, Haro G, Gubens MA, et al
    Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy.
    Clin Lung Cancer. 2021 Aug 20. pii: S1525-7304(21)00212.
    PubMed     Abstract available


  411. TAKADA K, Takamori S, Miura N, Shikada Y, et al
    Comments on 'The Impact of Beta Blockers on Survival Outcomes in Patients With Non-small-cell Lung Cancer Treated With Immune Checkpoint Inhibitors'.
    Clin Lung Cancer. 2021 Aug 10. pii: S1525-7304(21)00208.
    PubMed    


  412. LEE M, Patel D, Jofre S, Fidvi S, et al
    Large Cell Neuroendocrine Carcinoma Transformation as a Mechanism of Acquired Resistance to Osimertinib in Non-small Cell Lung Cancer: Case Report and Literature Review.
    Clin Lung Cancer. 2021 Aug 10. pii: S1525-7304(21)00206.
    PubMed    


    July 2021
  413. LI X, Chen X, He S, Chen H, et al
    The Application of Pigtail Catheters in Postoperative Drainage of Lung Cancer.
    Clin Lung Cancer. 2021 Jul 31. pii: S1525-7304(21)00191.
    PubMed     Abstract available


  414. REUSS JE, Gosa L, Liu SV
    Antibody Drug Conjugates in Lung Cancer: State of the Current Therapeutic Landscape and Future Developments.
    Clin Lung Cancer. 2021 Jul 25. pii: S1525-7304(21)00192.
    PubMed     Abstract available


  415. GJYSHI O, Lin SH, Pezzi TA, Ning MS, et al
    Care Patterns for Stereotactic Radiosurgery in Small Cell Lung Cancer Brain Metastases.
    Clin Lung Cancer. 2021 Jul 24. pii: S1525-7304(21)00184.
    PubMed     Abstract available


  416. UMEMURA S, Chen V, Chahine JJ, Kallakury B, et al
    Arginase Pathway Markers of Immune-Microenvironment in Thymic Epithelial Tumors and Small Cell Lung Cancer.
    Clin Lung Cancer. 2021 Jul 20. pii: S1525-7304(21)00187.
    PubMed     Abstract available


  417. WONG DJ, Bauer TM, Gordon MS, Bene-Tchaleu F, et al
    Safety and Clinical Activity of Atezolizumab Plus Ipilimumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Results From a Phase 1b Trial.
    Clin Lung Cancer. 2021 Jul 20. pii: S1525-7304(21)00183.
    PubMed     Abstract available


  418. SINGH S, Pavesi F, Steiling K, Asokan S, et al
    Risk Factors for Lung Cancer in an Underrepresented Safety-Net Screening Cohort.
    Clin Lung Cancer. 2021 Jul 19. pii: S1525-7304(21)00190.
    PubMed     Abstract available


  419. DE RUYSSCHER D, Ramalingam S, Urbanic J, Gerber DE, et al
    CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-S
    Clin Lung Cancer. 2021 Jul 19. pii: S1525-7304(21)00186.
    PubMed     Abstract available


  420. TAKAMORI S, Takada K, Shimokawa M, Okamoto T, et al
    Comments on "Lobe-specific Lymph Node Dissection in Clinical Stage IA Solid-dominant Non-small-cell Lung Cancer: A Propensity Score Matching Study".
    Clin Lung Cancer. 2021 Jul 7. pii: S1525-7304(21)00181.
    PubMed    


  421. MANGLAVITI S, Brambilla M, Signorelli D, Ferrara R, et al
    Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology.
    Clin Lung Cancer. 2021 Jul 5. pii: S1525-7304(21)00180.
    PubMed     Abstract available


  422. KOOPMAN B, Groen HJM, Schuuring E, Hiltermann TJN, et al
    Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer: Local Experience and Review of the Literature.
    Clin Lung Cancer. 2021 Jul 3. pii: S1525-7304(21)00178.
    PubMed     Abstract available


  423. TSUI DCC, Aisner D, Nijmeh H, Bao L, et al
    Tumor Shrinkage With Combination of Alectinib and Trastuzumab in a Patient With ALK-Rearranged Non-small Cell Lung Cancer Harboring HER2-Amplification as an Acquired Resistance Mechanism to ALK Inhibitor Therapy.
    Clin Lung Cancer. 2021 Jul 3. pii: S1525-7304(21)00179.
    PubMed    


  424. YIN J, Xi J, Liang J, Zhan C, et al
    Solid Components in the Mediastinal Window of Computed Tomography Define a Distinct Subtype of Subsolid Nodules in Clinical Stage I Lung Cancers.
    Clin Lung Cancer. 2021;22:324-331.
    PubMed     Abstract available


  425. KIM ES, Kish JK, Cseh A, Moehring B, et al
    Second-line Afatinib or Chemotherapy Following Immunochemotherapy for the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: Real-world Effectiveness and Safety From a Multisite Retrospective Chart Review in the USA.
    Clin Lung Cancer. 2021;22:292-300.
    PubMed     Abstract available


  426. SHIRASAWA M, Yoshida T, Takayanagi D, Shiraishi K, et al
    Activity and Immune Correlates of Programmed Death-1 Blockade Therapy in Patients With Advanced Large Cell Neuroendocrine Carcinoma.
    Clin Lung Cancer. 2021;22:282-291.
    PubMed     Abstract available


  427. TAKEDA M, Shimokawa M, Nakamura A, Nosaki K, et al
    A Phase II Study to Assess the Efficacy of Osimertinib in Patients With EGFR Mutation-positive NSCLC Who Developed Isolated CNS Progression (T790M-negative or Unknown) During First- or Second-generation EGFR-TKI or Systemic Disease Progression (T790M-
    Clin Lung Cancer. 2021;22:376-380.
    PubMed     Abstract available


  428. RAMALINGAM S, Dinan MA, Crawford J
    Treatment at Integrated Centers Might Bridge the Academic-Community Survival Gap in Patients With Metastatic Non-Small Cell Carcinoma of the Lung.
    Clin Lung Cancer. 2021;22:e646-e653.
    PubMed     Abstract available


  429. LAU SCM, Fares AF, Le LW, Mackay KM, et al
    Subtypes of EGFR- and HER2-Mutant Metastatic NSCLC Influence Response to Immune Checkpoint Inhibitors.
    Clin Lung Cancer. 2021;22:253-259.
    PubMed     Abstract available


  430. NAAMAN R, Lautenschlaeger T, Diab K
    Feasibility of Performing Transvascular Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration.
    Clin Lung Cancer. 2021;22:e595-e601.
    PubMed     Abstract available


  431. TAYLOR M, Grant SW, West D, Shackcloth M, et al
    Ninety-Day Mortality: Redefining the Perioperative Period After Lung Resection.
    Clin Lung Cancer. 2021;22:e642-e645.
    PubMed     Abstract available


  432. REGNERY S, Eichkorn T, Weykamp F, Held T, et al
    Safety and Efficacy of Stereotactic Body Radiotherapy in Ultracentral Lung Tumors Using a Risk-optimized Fractionation Scheme.
    Clin Lung Cancer. 2021;22:332-340.
    PubMed     Abstract available


  433. RALKI M, Serrien A, Lambert J, Leys M, et al
    Brown-Sequard Syndrome in a Desmoplastic Malignant Mesothelioma Patient: A Rare Complication.
    Clin Lung Cancer. 2021;22:e552-e554.
    PubMed    


  434. LEE PH, Chang GC
    Transformations First Into Squamous-Cell Carcinoma and Later Into Sarcomatoid Carcinoma After Acquired Resistance to Osimertinib in a Patient With EGFR-Mutant Lung Adenocarcinoma: Case Report.
    Clin Lung Cancer. 2021;22:e536-e541.
    PubMed    


  435. TAO L, Miao R, Mekhail T, Sun J, et al
    Prognostic Value of KRAS Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma.
    Clin Lung Cancer. 2021;22:e506-e511.
    PubMed     Abstract available


  436. KERKHOFF JW, Vreuls W, Vermeer LC
    Mesothelioma Micronodular Metastasis Pattern Confirmed by Transbronchial Cryobiopsy: Case Report.
    Clin Lung Cancer. 2021;22:e533-e535.
    PubMed    


  437. CORTINOVIS D, Grosso F, Carlucci L, Zucali PA, et al
    Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study.
    Clin Lung Cancer. 2021;22:361-370.
    PubMed     Abstract available


  438. SASSOROSSI C, Lococo F, Pogliani L, Tabacco D, et al
    Factors Affecting Long-Term Survival in Locally Advanced NSCLC Patients With Pathologic Complete Response After Induction Therapy Followed by Surgical Resection.
    Clin Lung Cancer. 2021;22:e542-e543.
    PubMed    


    June 2021
  439. YU HA, Goldberg SB, Le X, Piotrowska Z, et al
    Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD).
    Clin Lung Cancer. 2021 Jun 25. pii: S1525-7304(21)00157.
    PubMed     Abstract available


  440. YANG Y, Deng L, Yang Y, Zhang T, et al
    Efficacy and Safety of Combined Brain Radiotherapy and Immunotherapy in Non-Small-Cell Lung Cancer With Brain Metastases: A Systematic Review and Meta-Analysis.
    Clin Lung Cancer. 2021 Jun 24. pii: S1525-7304(21)00160.
    PubMed     Abstract available


  441. JACOBS CD, Mehta K, Gao J, Wang X, et al
    Nomogram Predicting Overall Survival Benefit of Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2021 Jun 24. pii: S1525-7304(21)00159.
    PubMed     Abstract available


  442. BARTA JA, Shusted CS, Ruane B, Pimpinelli M, et al
    Racial Differences in Lung Cancer Screening Beliefs and Screening Adherence.
    Clin Lung Cancer. 2021 Jun 13. pii: S1525-7304(21)00143.
    PubMed     Abstract available


  443. SAITO G, Kono M, Koyanagi Y, Miyashita K, et al
    Significance of Brain Imaging for Staging in Patients With Clinical Stage T1-2 N0 Non-Small-Cell Lung Cancer on Positron Emission Tomography/Computed Tomography.
    Clin Lung Cancer. 2021 Jun 13. pii: S1525-7304(21)00145.
    PubMed     Abstract available


  444. PINQUIE F, Cortot AB, Chevalier LM, Morel A, et al
    A Case Report of Successful Treatment With Crizotinib to Overcome Resistance to Osimertinib in an EGFR Mutated Non-Small-Cell Lung Cancer Patient Harboring an Acquired MET Exon 14 Mutation.
    Clin Lung Cancer. 2021 Jun 13. pii: S1525-7304(21)00142.
    PubMed    


  445. TSUI DCC, Kavanagh BD, Honce JM, Rossi C, et al
    Central Nervous System Response to Selpercartinib in Patient With RET-rearranged Non-small Cell Lung Cancer After Developing Leptomeningeal Disease on Pralsetinib.
    Clin Lung Cancer. 2021 Jun 12. pii: S1525-7304(21)00148.
    PubMed    


  446. HENDRIKS LEL, Remon J, Besse B
    Dorian Gray Syndrome of Upfront Immunotherapy in Patients With Non-Small-Cell Lung Cancer and High PD-L1 Expression.
    Clin Lung Cancer. 2021 Jun 12. pii: S1525-7304(21)00149.
    PubMed    


  447. SOCINSKI MA, Ozguroglu M, Villegas A, Daniel D, et al
    Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC).
    Clin Lung Cancer. 2021 Jun 12. pii: S1525-7304(21)00144.
    PubMed     Abstract available


    May 2021
  448. GADGEEL S, Hirsch FR, Kerr K, Barlesi F, et al
    Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK Trial.
    Clin Lung Cancer. 2021 May 30. pii: S1525-7304(21)00101.
    PubMed     Abstract available


  449. LI Y, Zhang Y, Jia X, Jiang P, et al
    Effect of Immune-Related Adverse Events and Pneumonitis on Prognosis in Advanced Non-Small Cell Lung Cancer: A Comprehensive Systematic Review and Meta-analysis.
    Clin Lung Cancer. 2021 May 28. pii: S1525-7304(21)00098.
    PubMed     Abstract available


  450. LEAL JL, Alexander M, Itchins M, Wright GM, et al
    EGFR Exon 20 Insertion Mutations: Clinicopathological Characteristics and Treatment Outcomes in Advanced Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2021 May 16. pii: S1525-7304(21)00093.
    PubMed     Abstract available


  451. RIESS JW, Reckamp KL, Frankel P, Longmate J, et al
    Erlotinib and Onalespib Lactate Focused on EGFR Exon 20 Insertion Non-Small Cell Lung Cancer (NSCLC): A California Cancer Consortium Phase I/II Trial (NCI 9878).
    Clin Lung Cancer. 2021 May 15. pii: S1525-7304(21)00094.
    PubMed     Abstract available


  452. RIESS JW, Rolfo C, Gandara DR
    Novel Clinical Trial Designs in Pursuit of Precision Oncology: Lung-MAP As a Model.
    Clin Lung Cancer. 2021;22:153-155.
    PubMed    


  453. PRINZI N, Rossi RE, Proto C, Leuzzi G, et al
    Recent Advances in the Management of Typical and Atypical Lung Carcinoids.
    Clin Lung Cancer. 2021;22:161-169.
    PubMed     Abstract available


  454. WHITE MN, Piotrowska Z, Stirling K, Liu SV, et al
    Combining Osimertinib With Chemotherapy in EGFR-Mutant NSCLC at Progression.
    Clin Lung Cancer. 2021;22:201-209.
    PubMed     Abstract available


  455. SAMUEL E, Lie G, Balasubramanian A, Hiong A, et al
    Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC.
    Clin Lung Cancer. 2021;22:e425-e430.
    PubMed     Abstract available


  456. GADOTTI LL, Nogueira Amorim Canedo FS, Ribeiro MFSA, Sacardo KP, et al
    Successful Drug Rechallenge Following Severe Acute Alectinib-induced Interstitial Lung Disease in a Patient With Advanced ALK-rearranged Lung Adenocarcinoma.
    Clin Lung Cancer. 2021;22:e481-e486.
    PubMed    


  457. ZENG YW, Liu Y, Qi Y, Yin MP, et al
    Bronchial Arterial Infusion Chemotherapy Plus Drug-eluting Bead Chemoembolization for Recurrence of Carina Region-induced Severe Right Main Bronchial Stenosis After Pneumonectomy.
    Clin Lung Cancer. 2021;22:e293-e297.
    PubMed    


  458. BEHRENS C, Rocha P, Parra ER, Feng L, et al
    Female Gender Predicts Augmented Immune Infiltration in Lung Adenocarcinoma.
    Clin Lung Cancer. 2021;22:e415-e424.
    PubMed     Abstract available


  459. PENG LP
    Regarding: MicroRNA-126 Targeting PIK3R2 Inhibits NSCLC A549 Cell Proliferation, Migration, and Invasion by Regulation of PTEN/PI3K/AKT Pathway.
    Clin Lung Cancer. 2021;22:e446-e450.
    PubMed    


  460. CHAPMAN BV, Ning MS, Farnia B, Mesko S, et al
    Postoperative Radiotherapy for Locally Advanced NSCLC: Implications for Shifting to Conformal, High-Risk Fields.
    Clin Lung Cancer. 2021;22:225-233.
    PubMed     Abstract available


  461. PATEL A, Roshkovan L, McNulty S, Alley E, et al
    Delayed-Phase Enhancement for Evaluation of Malignant Pleural Mesothelioma on Computed Tomography: A Prospective Cohort Study.
    Clin Lung Cancer. 2021;22:210-217.
    PubMed     Abstract available


  462. XIE Z, Gu Y, Xie X, Lin X, et al
    Lung Adenocarcinoma Harboring Concomitant EGFR Mutations and BRAF V600E Responds to a Combination of Osimertinib and Vemurafenib to Overcome Osimertinib Resistance.
    Clin Lung Cancer. 2021;22:e390-e394.
    PubMed    


  463. KOZLOV A, Pantel A, Iagaru A, Ikeda D, et al
    Pulmonary Adenocarcinoma Metastasis to the Breast Unexpectedly Discovered on Re-staging (18)F-FDG PET/CT in a Woman With a Normal Screening Mammogram.
    Clin Lung Cancer. 2021;22:e438-e441.
    PubMed    


  464. COUDERC AL, Tomasini P, Nouguerede E, Rey D, et al
    Older Patients Treated for Lung and Thoracic Cancers: Unplanned Hospitalizations and Overall Survival.
    Clin Lung Cancer. 2021;22:e405-e414.
    PubMed     Abstract available


  465. TSUTANI Y, Nakayama H, Ito H, Handa Y, et al
    Long-Term Outcomes After Sublobar Resection Versus Lobectomy in Patients With Clinical Stage IA Lung Adenocarcinoma Meeting the Node-Negative Criteria Defined by High-Resolution Computed Tomography and [(18)F]-Fluoro-2-Deoxy-d-Glucose Positron Emissio
    Clin Lung Cancer. 2021;22:e431-e437.
    PubMed     Abstract available


  466. KANDER EM, Shah MH, Zhou Y, Goyal A, et al
    Response to the Selective RET Inhibitor Selpercatinib (LOXO-292) in a Patient With RET Fusion-positive Atypical Lung Carcinoid.
    Clin Lung Cancer. 2021;22:e442-e445.
    PubMed    


  467. KUNTE S, Stevenson J
    A Case of HLA-DRB1-MET Rearranged Lung Adenocarcinoma With Rapid Response to Crizotinib.
    Clin Lung Cancer. 2021;22:e298-e300.
    PubMed    


  468. WANG S, Wu X, Zhao J, Chen H, et al
    Next-Generation Sequencing Identified a Novel Crizotinib-Sensitive PLB1-ALK Rearrangement in Lung Large-Cell Neuroendocrine Carcinoma.
    Clin Lung Cancer. 2021;22:e366-e370.
    PubMed    


  469. TAMIYA A, Isa SI, Taniguchi Y, Nakagawa H, et al
    Prospective Observational Study of Treatment Resistance-related Gene Screening Using Plasma Circulating Tumor DNA in Third-generation EGFR-TKI Osimertinib Therapy (Elucidator).
    Clin Lung Cancer. 2021;22:e336-e341.
    PubMed     Abstract available


  470. ZHOU M, Joshi N, Raj KP, Wakelee H, et al
    PD-1/PD-L1 Checkpoint Inhibitor Immunotherapy for Malignant Pleural Mesothelioma: Case Series and Literature Review.
    Clin Lung Cancer. 2021;22:e329-e335.
    PubMed    


    April 2021
  471. HAMADA A, Soh J, Hata A, Nakamatsu K, et al
    Phase II Study of Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage IIIA-B (Discrete N2) Non-small-cell Lung Cancer: SQUAT trial (WJOG 12119L).
    Clin Lung Cancer. 2021 Apr 27. pii: S1525-7304(21)00090.
    PubMed     Abstract available


  472. OYANAGI J, Koh Y, Sato K, Teraoka S, et al
    Bloodborne Cytokines for Predicting Clinical Benefits and Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated With Anti-Programmed Cell Death 1 Inhibitors.
    Clin Lung Cancer. 2021 Apr 27. pii: S1525-7304(21)00091.
    PubMed     Abstract available


  473. BYERS LA, Navarro A, Schaefer E, Johnson M, et al
    A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer.
    Clin Lung Cancer. 2021 Apr 24. pii: S1525-7304(21)00089.
    PubMed     Abstract available


  474. FISHER A, Kim S, Farhat D, Belzer K, et al
    Risk Factors Associated with a Second Primary Lung Cancer in Patients with an Initial Primary Lung Cancer.
    Clin Lung Cancer. 2021 Apr 23. pii: S1525-7304(21)00088.
    PubMed     Abstract available


  475. MERKHOFER CM, Eaton KD, Martins RG, Ramsey SD, et al
    Impact of Clinical Trial Participation on Survival of Patients with Metastatic Non-Small Cell Lung Cancer.
    Clin Lung Cancer. 2021 Apr 22. pii: S1525-7304(21)00087.
    PubMed     Abstract available


  476. RAEZ LE, Carracedo C, Drusbosky LM, Velez M, et al
    EGFR L718V (+)/T790M (-) as a Mechanism of Resistance in Patients with Metastatic Non-small-cell Lung Cancer with EGFR L858R Mutations.
    Clin Lung Cancer. 2021 Apr 9. pii: S1525-7304(21)00072.
    PubMed    


    March 2021
  477. MORAN A, Wang Y, Dyer BA, Yip SSF, et al
    Prognostic Value of Computed Tomography and/or (18)F-Fluorodeoxyglucose Positron Emission Tomography Radiomics Features in Locally Advanced Non-small Cell Lung Cancer.
    Clin Lung Cancer. 2021 Mar 27. pii: S1525-7304(21)00069.
    PubMed     Abstract available


  478. ARRIETA O, Varela-Santoyo E, Cardona AF, Sanchez-Reyes R, et al
    Association of Carcinoembryonic Antigen Reduction With Progression-free and Overall Survival Improvement in Advanced Non-small-cell Lung Cancer.
    Clin Lung Cancer. 2021 Mar 27. pii: S1525-7304(21)00068.
    PubMed     Abstract available


  479. KAO C, Powers E, Wu Y, Datto MB, et al
    Predictive Value of Combining Biomarkers for Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
    Clin Lung Cancer. 2021 Mar 27. pii: S1525-7304(21)00071.
    PubMed     Abstract available


  480. SHEN Q, Kalyani FS, Qu J, Chen Z, et al
    A Case of Small Cell Lung Carcinoma Harboring an EML4-ALK Fusion with Partial Response to Crizotinib.
    Clin Lung Cancer. 2021 Mar 26. pii: S1525-7304(21)00066.
    PubMed    


  481. WEISS J, Goldschmidt J, Andric Z, Dragnev KH, et al
    Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies.
    Clin Lung Cancer. 2021 Mar 26. pii: S1525-7304(21)00064.
    PubMed     Abstract available


  482. BRAINSON CF, Huang B, Chen Q, McLouth LE, et al
    Description of a Lung Cancer Hotspot: Disparities in Lung Cancer Histology, Incidence, and Survival in Kentucky and Appalachian Kentucky.
    Clin Lung Cancer. 2021 Mar 26. pii: S1525-7304(21)00061.
    PubMed     Abstract available


  483. KELLER A, Ghanta S, Rodriguez-Lopez JL, Patel A, et al
    Utility of Prophylactic Cranial Irradiation for Extensive-Stage Small-Cell Lung Cancer in the MRI Screening Era.
    Clin Lung Cancer. 2021 Mar 26. pii: S1525-7304(21)00063.
    PubMed     Abstract available


  484. CABEZON-GUTIERREZ L, Custodio-Cabello S, Palka-Kotlowska M, Alonso-Viteri S, et al
    Biomarkers of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Beyond PD-L1.
    Clin Lung Cancer. 2021 Mar 24. pii: S1525-7304(21)00060.
    PubMed     Abstract available


  485. DALL'OLIO FG, Gelsomino F, Conci N, Marcolin L, et al
    PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non-small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors.
    Clin Lung Cancer. 2021 Mar 16. pii: S1525-7304(21)00057.
    PubMed     Abstract available


  486. UPRETY D
    CheckMate 743: A Glimmer of Hope for Malignant Pleural Mesothelioma.
    Clin Lung Cancer. 2021;22:71-73.
    PubMed    


  487. TAKEYASU Y, Yoshida T, Shibaki R, Matsumoto Y, et al
    Differential Efficacy of Pembrolizumab According to Metastatic Sites in Patients With PD-L1 Strongly Positive (TPS >/= 50%) NSCLC.
    Clin Lung Cancer. 2021;22:127-133.
    PubMed     Abstract available


  488. MOUNTZIOS G, de Toma A, Economopoulou P, Friedlaender A, et al
    Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy.
    Clin Lung Cancer. 2021;22:e180-e192.
    PubMed     Abstract available


  489. ZHANG C, He Z, Cheng J, Cao J, et al
    Surgical Outcomes of Lobectomy Versus Limited Resection for Clinical Stage I Ground-Glass Opacity Lung Adenocarcinoma 2 Centimeters or Smaller.
    Clin Lung Cancer. 2021;22:e160-e168.
    PubMed     Abstract available


  490. SHAH R, Klotz LV, Chung I, Feisst M, et al
    A Phase II Trial of Nivolumab With Chemotherapy Followed by Maintenance Nivolumab in Patients With Pleural Mesothelioma After Surgery: The NICITA Study Protocol.
    Clin Lung Cancer. 2021;22:142-146.
    PubMed     Abstract available


  491. LIN G, Liu Y, Li H, Chen S, et al
    Emergence of NOTCH2-NTRK1 After Osimertinib in a Patient With Lung Adenocarcinoma With Neuroendocrine Differentiation.
    Clin Lung Cancer. 2021;22:e157-e159.
    PubMed    


  492. SUDA K, Sakai K, Obata K, Ohara S, et al
    Inter- and Intratumor Heterogeneity of EGFR Compound Mutations in Non-Small Cell Lung Cancers: Analysis of Five Cases.
    Clin Lung Cancer. 2021;22:e141-e145.
    PubMed     Abstract available


    February 2021
  493. KOGURE Y, Hashimoto H, Oki M
    A Randomized Phase III Study of Pembrolizumab Versus Pembrolizumab-Carboplatin-Pemetrexed for Locally Advanced or Metastatic Nonsquamous Non-small-cell Lung Cancer with PD-L1 50% or more (LAPLACE-50): Study Protocol.
    Clin Lung Cancer. 2021 Feb 19. pii: S1525-7304(21)00031.
    PubMed     Abstract available


    January 2021
  494. RIESS JW, Frankel P, Shackelford D, Dunphy M, et al
    Phase 1 Trial of MLN0128 (Sapanisertib) and CB-839 HCl (Telaglenastat) in Patients With Advanced NSCLC (NCI 10327): Rationale and Study Design.
    Clin Lung Cancer. 2021;22:67-70.
    PubMed     Abstract available


  495. URBAN L, Doczi R, Vodicska B, Tihanyi D, et al
    Major Clinical Response to Afatinib Monotherapy in Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion Mutation.
    Clin Lung Cancer. 2021;22:e112-e115.
    PubMed    


  496. STEBER CR, Hughes RT, Soike MH, Jacobson T, et al
    Five- Versus Ten-Fraction Regimens of Stereotactic Body Radiation Therapy for Primary and Metastatic NSCLC.
    Clin Lung Cancer. 2021;22:e122-e131.
    PubMed     Abstract available


  497. NAGASAKA M, Fisher A, Chowdhury T, Ge Y, et al
    PLEKHH2-ALK: A Novel In-frame Fusion With Durable Response to Alectinib: Utilizing RNA Sequencing in Search for Hidden Gene Fusions Susceptible to Targeted Therapy.
    Clin Lung Cancer. 2021;22:e51-e53.
    PubMed    


  498. EMEREL L, Trejo Bittar H, Okusanya OT
    A Rare Presentation of Primary Pulmonary Synovial Sarcoma.
    Clin Lung Cancer. 2021;22:e48-e50.
    PubMed    


  499. CHEN K, Zhang F, Pan G, Sheng J, et al
    A Case of Resistance to Selective RET-TKI Therapy With Pleural-Genotyped MET Amplification and Response to Crizotinib.
    Clin Lung Cancer. 2021;22:e1-e4.
    PubMed    


    March 2020
  500. GELSOMINO F, Di Federico A, Filippini DM, Dall'Olio FG, et al
    Overcoming Primary Resistance to PD-1 Inhibitor With Anti-PD-L1 Agent in Squamous-Cell NSCLC: Case Report.
    Clin Lung Cancer. 2020;21:e45-e48.
    PubMed    


  501. BARBOSA MVR, Cordeiro de Lima VC, Formiga MN, Andrade de Paula CA, et al
    High Prevalence of EGFR Mutations in Lung Adenocarcinomas From Brazilian Patients Harboring the TP53 p.R337H Variant.
    Clin Lung Cancer. 2020;21:e37-e44.
    PubMed    


  502. MATSUBARA T, Uchi H, Haratake N, Takamori S, et al
    Acute Generalized Exanthematous Pustulosis Caused by the Combination of Pembrolizumab Plus Chemotherapy in a Patient With Squamous-Cell Carcinoma.
    Clin Lung Cancer. 2020;21:e54-e56.
    PubMed    


  503. MAZZASCHI G, Bordi P, Fioretzaki R, Gnetti L, et al
    Nivolumab-Induced Guillain-Barre Syndrome Coupled With Remarkable Disease Response in a Case of Heavily Pretreated Lung Adenocarcinoma.
    Clin Lung Cancer. 2020;21:e65-e73.
    PubMed    


  504. TANNER NT, Brasher PB, Jett J, Silvestri GA, et al
    Effect of a Rule-in Biomarker Test on Pulmonary Nodule Management: A Survey of Pulmonologists and Thoracic Surgeons.
    Clin Lung Cancer. 2020;21:e89-e98.
    PubMed     Abstract available


  505. ZHANG Y, Yu M, Yuan M, Chen R, et al
    Identification of a Novel RBPMS-ROS1 Fusion in an Adolescent Patient With Microsatellite-instable Advanced Lung Adenocarcinoma Sensitive to Crizotinib: A Case Report.
    Clin Lung Cancer. 2020;21:e78-e83.
    PubMed    


  506. KINSLOW CJ, May MS, Saqi A, Shu CA, et al
    Large-Cell Neuroendocrine Carcinoma of the Lung: A Population-Based Study.
    Clin Lung Cancer. 2020;21:e99-e113.
    PubMed     Abstract available


  507. ERSEK JL, Symanowski JT, Han Y, Howard A, et al
    Pulmonary Carcinosarcoma: A Surveillance, Epidemiology, and End Results (SEER) Analysis.
    Clin Lung Cancer. 2020;21:160-170.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.